
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/base_style-CPPDhfna.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-BepKMsUl.js"></script>

  <link rel="stylesheet" href="/static/assets/article_style-DUfI1jZp.css" />
<link rel="stylesheet" href="/static/assets/style-BOrsu84o.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-D3wJHomh.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="18DE241B930AEF3300241B004861828D.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="bmcmedicine">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12642075/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="BMC Medicine">
<meta name="citation_title" content="The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis">
<meta name="citation_author" content="Christina Dam Bjerregaard Sillassen">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author_institution" content="Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Region of Zealand Denmark">
<meta name="citation_author_institution" content="Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark">
<meta name="citation_author" content="Johanne Juul Petersen">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author" content="Pascal Faltermeier">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author_institution" content="Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark">
<meta name="citation_author" content="Delal Yucel">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author" content="Faiza Siddiqui">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author" content="Rebecca Kjær Andersen">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author" content="Leonardo Graever">
<meta name="citation_author_institution" content="Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark">
<meta name="citation_author_institution" content="Department of Clinical Medicine, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil">
<meta name="citation_author" content="Jonas Leth Bjerg">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author" content="Caroline Barkholt Kamp">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author" content="Johannes Grand">
<meta name="citation_author_institution" content="Department of Cardiology, Copenhagen University Hospital - Amager-Hvidovre Hospital, Copenhagen, Denmark">
<meta name="citation_author" content="Helena Dominguez">
<meta name="citation_author_institution" content="Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark">
<meta name="citation_author_institution" content="Department of Cardiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author" content="Anne Frølich">
<meta name="citation_author_institution" content="Innovation and Research Centre for Multimorbidity, Slagelse Hospital, Slagelse, Region of Zealand Denmark">
<meta name="citation_author_institution" content="Section of General Practice, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark">
<meta name="citation_author" content="Peter Gæde">
<meta name="citation_author_institution" content="Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Region of Zealand Denmark">
<meta name="citation_author_institution" content="Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark">
<meta name="citation_author" content="Christian Gluud">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author_institution" content="Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark">
<meta name="citation_author" content="Ole Mathiesen">
<meta name="citation_author_institution" content="Department of Anaesthesiology, Centre for Anaesthesiological Research, Zealand University Hospital, Køge, Denmark">
<meta name="citation_author_institution" content="Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark">
<meta name="citation_author" content="Janus Christian Jakobsen">
<meta name="citation_author_institution" content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark">
<meta name="citation_author_institution" content="Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark">
<meta name="citation_publication_date" content="2025 Nov 24">
<meta name="citation_volume" content="23">
<meta name="citation_firstpage" content="654">
<meta name="citation_doi" content="10.1186/s12916-025-04486-0">
<meta name="citation_pmid" content="41286875">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12642075/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12642075/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12642075/pdf/12916_2025_Article_4486.pdf">
<meta name="description" content="Semaglutide’s disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with ...">
<meta name="og:title" content="The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Semaglutide’s disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12642075/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12642075">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12916-025-04486-0"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12916_2025_Article_4486.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12642075%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12642075/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12642075/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12642075/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-bmcmedicine.png" alt="BMC Medicine logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to BMC Medicine" title="Link to BMC Medicine" shape="default" href="https://bmcmedicine.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">BMC Med</button></div>. 2025 Nov 24;23:654. doi: <a href="https://doi.org/10.1186/s12916-025-04486-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12916-025-04486-0</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22BMC%20Med%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22BMC%20Med%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22BMC%20Med%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22BMC%20Med%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sillassen%20CDB%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Christina Dam Bjerregaard Sillassen</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Christina Dam Bjerregaard Sillassen</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">
<sup>2</sup>Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Region of Zealand Denmark </div>
<div class="p">
<sup>3</sup>Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sillassen%20CDB%22%5BAuthor%5D" class="usa-link"><span class="name western">Christina Dam Bjerregaard Sillassen</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petersen%20JJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Johanne Juul Petersen</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Johanne Juul Petersen</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Petersen%20JJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Johanne Juul Petersen</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Faltermeier%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Pascal Faltermeier</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Pascal Faltermeier</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">
<sup>3</sup>Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Faltermeier%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Pascal Faltermeier</span></a>
</div>
</div>
<sup>1,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yucel%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Delal Yucel</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Delal Yucel</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yucel%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Delal Yucel</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Siddiqui%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Faiza Siddiqui</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Faiza Siddiqui</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Siddiqui%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Faiza Siddiqui</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Andersen%20RK%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Rebecca Kjær Andersen</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Rebecca Kjær Andersen</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Andersen%20RK%22%5BAuthor%5D" class="usa-link"><span class="name western">Rebecca Kjær Andersen</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Graever%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Leonardo Graever</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Leonardo Graever</span></h3>
<div class="p">
<sup>4</sup>Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark </div>
<div class="p">
<sup>5</sup>Department of Clinical Medicine, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Graever%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Leonardo Graever</span></a>
</div>
</div>
<sup>4,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bjerg%20JL%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Jonas Leth Bjerg</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Jonas Leth Bjerg</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bjerg%20JL%22%5BAuthor%5D" class="usa-link"><span class="name western">Jonas Leth Bjerg</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kamp%20CB%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Caroline Barkholt Kamp</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Caroline Barkholt Kamp</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kamp%20CB%22%5BAuthor%5D" class="usa-link"><span class="name western">Caroline Barkholt Kamp</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Grand%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Johannes Grand</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Johannes Grand</span></h3>
<div class="p">
<sup>6</sup>Department of Cardiology, Copenhagen University Hospital - Amager-Hvidovre Hospital, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Grand%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Johannes Grand</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dominguez%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Helena Dominguez</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Helena Dominguez</span></h3>
<div class="p">
<sup>4</sup>Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark </div>
<div class="p">
<sup>7</sup>Department of Cardiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, The Capital Region, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dominguez%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Helena Dominguez</span></a>
</div>
</div>
<sup>4,</sup><sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fr%C3%B8lich%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Anne Frølich</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Anne Frølich</span></h3>
<div class="p">
<sup>8</sup>Innovation and Research Centre for Multimorbidity, Slagelse Hospital, Slagelse, Region of Zealand Denmark </div>
<div class="p">
<sup>9</sup>Section of General Practice, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fr%C3%B8lich%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Anne Frølich</span></a>
</div>
</div>
<sup>8,</sup><sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22G%C3%A6de%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Peter Gæde</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Peter Gæde</span></h3>
<div class="p">
<sup>2</sup>Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Region of Zealand Denmark </div>
<div class="p">
<sup>3</sup>Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22G%C3%A6de%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Peter Gæde</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gluud%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Christian Gluud</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Christian Gluud</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">
<sup>3</sup>Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gluud%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Christian Gluud</span></a>
</div>
</div>
<sup>1,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mathiesen%20O%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Ole Mathiesen</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Ole Mathiesen</span></h3>
<div class="p">
<sup>10</sup>Department of Anaesthesiology, Centre for Anaesthesiological Research, Zealand University Hospital, Køge, Denmark </div>
<div class="p">
<sup>11</sup>Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mathiesen%20O%22%5BAuthor%5D" class="usa-link"><span class="name western">Ole Mathiesen</span></a>
</div>
</div>
<sup>10,</sup><sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jakobsen%20JC%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Janus Christian Jakobsen</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Janus Christian Jakobsen</span></h3>
<div class="p">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div class="p">
<sup>3</sup>Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jakobsen%20JC%22%5BAuthor%5D" class="usa-link"><span class="name western">Janus Christian Jakobsen</span></a>
</div>
</div>
<sup>1,</sup><sup>3</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital -Rigshospitalet, The Capital Region, Copenhagen, Denmark </div>
<div id="Aff2">
<sup>2</sup>Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Region of Zealand Denmark </div>
<div id="Aff3">
<sup>3</sup>Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark </div>
<div id="Aff4">
<sup>4</sup>Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark </div>
<div id="Aff5">
<sup>5</sup>Department of Clinical Medicine, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil </div>
<div id="Aff6">
<sup>6</sup>Department of Cardiology, Copenhagen University Hospital - Amager-Hvidovre Hospital, Copenhagen, Denmark </div>
<div id="Aff7">
<sup>7</sup>Department of Cardiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, The Capital Region, Copenhagen, Denmark </div>
<div id="Aff8">
<sup>8</sup>Innovation and Research Centre for Multimorbidity, Slagelse Hospital, Slagelse, Region of Zealand Denmark </div>
<div id="Aff9">
<sup>9</sup>Section of General Practice, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark </div>
<div id="Aff10">
<sup>10</sup>Department of Anaesthesiology, Centre for Anaesthesiological Research, Zealand University Hospital, Køge, Denmark </div>
<div id="Aff11">
<sup>11</sup>Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jun 7; Accepted 2025 Oct 27; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12642075  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/41286875/" class="usa-link">41286875</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Semaglutide’s disease-specific weight-reducing effects are well established, but its adverse effects, which may not be disease-specific, have not been systematically assessed. The aim of this review was to assess the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">We searched six electronic databases and other sources from inception to 31/03/2025. Randomized trials comparing semaglutide (oral or subcutaneous) with placebo in patients at increased risk of cardiovascular events were eligible. The search identified 8370 records. Two review authors independently screened all studies for eligibility. Data were synthesized using meta-analysis and Trial Sequential Analysis (TSA). Risk of bias was assessed with the Cochrane Risk of Bias tool – version 2; our eight-step procedure was used to assess if the thresholds for statistical significance were crossed, and the certainty of the evidence was assessed by the Grading of Recommendations, Assessment, Development and Evaluations. Primary outcomes were all-cause mortality and serious adverse events (SAEs). Secondary outcomes included myocardial infarction and non-serious adverse events (AEs).</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">The analysis included 50 trials, with a total of 54,972 participants randomized. Nineteen (38%) enrolled participants with type 2 diabetes (T2DM), 17 (34%) with overweight, 5 (10%) with T2DM and chronic kidney disease, 5 (10%) with T2DM and overweight, and 4 (8%) involved other patient populations.</p>
<p id="Par4">Meta-analysis and TSA showed evidence of beneficial effects of semaglutide on all-cause mortality (relative risk (RR) 0.85; 95% CI 0.79 to 0.91; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01) and myocardial infarction (RR 0.77, 95% CI 0.69 to 0.85; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01). None of these analyses showed signs of heterogeneity, and the evidence was of high certainty. Meta-analysis showed that semaglutide decreased the risk of SAEs (RR 0.93, 95% CI 0.88 to 0.98; <em>I</em><sup>2</sup> = 24.1%; <em>p</em> &lt; 0.01), but increased the risk of several non-serious gastrointestinal AEs including nausea (RR 3.00, 95% CI 2.63 to 3.42), vomiting (RR 4.12, 95% CI 3.47 to 4.90), and diarrhea (RR 1.88, 95% CI 1.68 to 2.11).</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusions</h3>
<p id="Par5">In patients at increased risk of cardiovascular events, semaglutide reduced the risk of mortality, SAEs, and myocardial infarction but increased the risk of several non-serious gastrointestinal AEs.</p></section><section id="sec5"><h3 class="pmc_sec_title">Registration</h3>
<p id="Par6">PROSPERO, CRD42024499511.</p></section><section id="sec6"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s12916-025-04486-0.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Semaglutide, Placebo, Safety, Systematic review, Meta-analysis, Trial sequential analysis</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Background</h2>
<p id="Par32">Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA), a class of drugs that mimic the effects of incretin hormones [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. GLP-1 RAs enhance satiety and reduce food intake, primarily through metabolic effects such as delayed gastric emptying and reduced gastrointestinal motility [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>].
</p>
<p id="Par33">The U.S. Food &amp; Drug Administration approved semaglutide for treatment of type 2 diabetes mellitus in 2017, for treatment of obesity and overweight with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, or type 2 diabetes mellitus) in 2021 and for the treatment of metabolic-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>–<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. Semaglutide is available in a peroral (Rybelsus®) [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>] and subcutaneous formulations (Ozempic® and Wegovy®) [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>].
</p>
<p id="Par34">The disease-specific weight-reducing and anti-hyperglycemic effects of semaglutide are well established [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>–<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. However, the adverse effects associated with semaglutide use, which may not be disease-specific, have not previously been systematically assessed in all patients at increased risk of cardiovascular events [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. A meta-analysis by Rivera et al. [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>] included 23 trials comparing semaglutide with placebo and found that semaglutide is associated with an increased risk of nausea and vomiting. However, the meta-analysis did not include all patient groups at increased risk of cardiovascular events and did not apply Trial Sequential Analysis, reflecting differences in scope and methodology. In addition, the authors reported a limited set of adverse events and included only studies published up to 2023.</p>
<p id="Par35">This systematic review aims to investigate the adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events. With the increasing use of semaglutide, this systematic review is warranted and needed.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<p id="Par36">This systematic review, which includes meta-analysis and Trial Sequential Analysis, is reported based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Additional file 1: Figure S1) [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. The detailed methodology is described in detail in our published protocol (PROSPERO ID: CRD42024499511) [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>].</p>
<p id="Par37">In short, an experienced information specialist searched the Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval System Online (MEDLINE) (MEDLINE Ovid), Excerpta Medica database (EMBASE) (Embase Ovid), Latin American and Caribbean Health Sciences Literature (LILACS) (VHL Regional Portal), Science Citation Index Expanded (SCI-EXPANDED) (Web of Science) and Conference Proceedings Citation Index—Science (CPCI-S) (Web of Science) to identify relevant trials. All databases were searched from their inception to March 31, 2025. We also searched clinical trial registries (clinicaltrials.gov, clinicaltrialregister.eu, who.int/ictrp, chictr.org.cn) of the World to identify unpublished trials. We used a combination of terms related to the intervention, the comparator, and randomized trials. The search was not restricted by patient population or outcomes. Key search terms included “semaglutide,” “glucagon-like peptide-1 agonist,” “randomized,” “trial,” and “placebo.” For a detailed search strategy for all electronic databases, see online Supplementary material.</p>
<p id="Par38">Four authors working in pairs (CDBS paired with DY, LG, or RKA) independently screened relevant trials. Seven authors working in pairs (CDBS paired with JJP, PF, DY, FS, RKA, or JLB) independently extracted data using a standardized data extraction sheet and assessed the risks of bias based on the Cochrane Risk of Bias tool, version 2 (RoB 2) [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Intention-to-treat (ITT) data were extracted when available; otherwise, modified ITT data were used. Any disagreements were resolved through internal discussion or discussion with a third author (JCJ).</p>
<p id="Par39">Trials were included regardless of language, publication status, publication year, and publication type. We included all patients at increased risk of cardiovascular events. If a trial did not explicitly define participants as being at increased risk of cardiovascular events, we considered them to be at increased risk if they had any of the following: established cardiovascular disease, overweight with weight-related comorbidities, obesity, heart failure, diabetes mellitus, MASH, hypertension, or chronic kidney disease. As experimental intervention, we accepted any type of semaglutide (e.g., oral or subcutaneous formulation). As control intervention, we accepted placebo or “no intervention” (e.g., semaglutide plus usual care versus usual care (no placebo control)). Cointerventions were allowed if they were planned to be used equally in the intervention and control groups (i.e., if the co-interventions were identical in the different treatment arms). Common co-interventions included dietary advice, calorie deficit, and physical activity.</p>
<p id="Par40">If a trial enrolled participants representing mixed-risk populations (for example, individuals with obesity with or without type 2 diabetes), we included the trial based on the overall effect estimate for the entire study population, provided that the entire cohort could be considered at increased risk of cardiovascular events.</p>
<p id="Par41">We contacted trial authors by email to obtain missing or insufficiently reported data.</p>
<section id="Sec3"><h3 class="pmc_sec_title">Outcomes and subgroup analyses</h3>
<p id="Par42">The primary outcomes were all-cause mortality and serious adverse events as defined by the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. Secondary outcomes were myocardial infarction, stroke, all-cause hospitalization and adverse events. Exploratory outcomes were pancreatitis, cancer, suicide or suicide attempt, a composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or non-fatal stroke, and vision change (blurred vision, retinopathy, or macular complications). All outcomes were assessed at the maximum follow-up time point. We planned multiple subgroup analyses for the primary outcomes [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>].</p></section><section id="Sec4"><h3 class="pmc_sec_title">Assessment of statistical significance</h3>
<p id="Par43">We performed the meta-analyses according to the <em>Cochrane Handbook of Systematic Reviews of Interventions</em> [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>], Keus et al. [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>], and the eight-step assessment suggested by Jakobsen et al. [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. We planned to assess a total of two primary outcomes and applied a significance threshold of <em>p</em> ≤ 0.03 to account for multiple testing. This approach is based on methodological guidance by Jakobsen et al. [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>], which recommends adjusting the alpha level when evaluating multiple primary outcomes to control the overall risk of type I error, while avoiding the conservativeness of the standard Bonferroni correction. We assessed the intervention effects with both random-effects meta-analysis [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>] and fixed-effect meta-analysis for each treatment comparison separately [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. To ensure that the results and conclusions were not dependent on the choice of meta-analytical method, we pre-specified that the most conservative estimate, defined as the model with the highest <em>p</em>-value, would be reported as the primary result, while the alternative model was considered a sensitivity analysis [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. When more than five trials reported rare events (defined as five or fewer events) or zero events for a given outcome, we applied beta-binomial regression to meta-analyze data [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>].</p>
<p id="Par44">Due to a large number of different specific serious adverse events reported in some trials (up to more than 1700 different serious adverse events in one trial), we decided only to meta-analyze a serious adverse event if at least one trial in either the intervention group or placebo group had five or more events.</p>
<p id="Par45">We analyzed data using the statistical software Stata version 18.0 [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. Trial Sequential Analysis was used to assess the statistical power of the meta-analyses by estimating the diversity-adjusted required information size (the meta-analytic sample size) [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. Conducting Trial Sequential Analysis is particularly important when evaluating outcomes with expected low event rates, such as all-cause mortality, myocardial infarction, and stroke, in order to ensure the interpretability of the results, assess the reliability of the meta-analysis, and reduce the risk of both overestimation and underestimation of effect sizes. We conducted post-hoc meta-regression on the primary outcomes and sensitivity analyses on the primary and secondary outcomes. We used Grading Recommendations Assessment Development Evaluation (GRADE) to assess the certainty of evidence [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>, <a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>–<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. We assessed possible publication bias by visual inspection of funnel plots and by Egger’s and Begg’s test [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>, <a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>].</p></section></section><section id="Sec5"><h2 class="pmc_sec_title">Results</h2>
<p id="Par46">The literature search identified 8370 records after duplicates were removed. We included 50 trials, randomizing 54,972 participants to semaglutide (30,281 participants) or placebo (24,691 participants) (see Fig. <a href="#Fig1" class="usa-link">1</a>) [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>–<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. Additionally, the search identified five crossover trials without results before crossover [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>–<a href="#CR87" class="usa-link" aria-describedby="CR87">87</a>] and one withdrawal trial [<a href="#CR88" class="usa-link" aria-describedby="CR88">88</a>].</p>
<figure class="fig xbox font-sm" id="Fig1"><h3 class="obj_head">Fig. 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12642075_12916_2025_4486_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89a2/12642075/cd44501ebf40/12916_2025_4486_Fig1_HTML.jpg" loading="lazy" id="MO1" height="934" width="709" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram of the study selection process. A total of 50 trials were included in this review. In addition, 96 ongoing studies, five cross-over trials without results before cross-over, and one withdrawal trial were identified, but not included</p></figcaption></figure><section id="Sec6"><h3 class="pmc_sec_title">Characteristics of included studies</h3>
<p id="Par47">The characteristics of the included trials can be found online in Table <a href="#Tab1" class="usa-link">1</a>. Twenty-three of 50 (46%) of the trials were at low risk of bias (corresponding to 46380/54942 (84.4%) of all included participants); all remaining trials were at high risk of bias (Additional file 1: Table S1) [<a href="#CR89" class="usa-link" aria-describedby="CR89">89</a>–<a href="#CR128" class="usa-link" aria-describedby="CR128">128</a>]. The maximum follow-up time ranged from 15.5 weeks to 47.5 months (mean) after randomization. Nineteen of 50 (38%) of trials investigated participants with type 2 diabetes; 17/50 (34%) overweight; 5/50 (10%) type 2 diabetes and chronic kidney disease; 5/50 (10%) type 2 diabetes and overweight; 1/50 (2%) type 2 diabetes and heart failure with preserved ejection fraction (HFpEF); 1/50 (2%) overweight and HFpEF, 1/50 (2%) metabolic dysfunction-associated steatohepatitis, and 1/50 (2%) overweight and human immunodeficiency virus (HIV)−1.
</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>The included trials with information about funding, overall patient group, type of semaglutide and the dose, and the number of randomized participants to semaglutide and placebo</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1"><strong>Funding</strong></th>
<th align="left" colspan="1" rowspan="1"><strong>Overall patient group(s)</strong></th>
<th align="left" colspan="1" rowspan="1"><strong>Route of administration</strong></th>
<th align="left" colspan="1" rowspan="1"><strong>Dose (after dose escalation)</strong></th>
<th align="left" colspan="1" rowspan="1"><strong>Participants randomized to semaglutide</strong></th>
<th align="left" colspan="1" rowspan="1"><strong>Participants randomized to placebo</strong></th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"> Aroda 2019 [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral daily</td>
<td align="left" colspan="1" rowspan="1">3, 7, and 14 mg</td>
<td align="left" colspan="1" rowspan="1">525</td>
<td align="left" colspan="1" rowspan="1">178</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Blüher 2024 [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]
</td>
<td align="left" colspan="1" rowspan="1">Boehringer Ingelheim Pharma GmbH &amp; Co</td>
<td align="left" colspan="1" rowspan="1">T2DM and overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">50</td>
<td align="left" colspan="1" rowspan="1">59</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Davies 2017 [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral daily and sub-cutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.5, 5, 10, 20, and 40 mg and 1 mg</td>
<td align="left" colspan="1" rowspan="1">561</td>
<td align="left" colspan="1" rowspan="1">71</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Davies 2021 [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM and overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 and 2.4 mg</td>
<td align="left" colspan="1" rowspan="1">807</td>
<td align="left" colspan="1" rowspan="1">403</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Flint 2021 [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous daily</td>
<td align="left" colspan="1" rowspan="1">0.4 mg</td>
<td align="left" colspan="1" rowspan="1">34</td>
<td align="left" colspan="1" rowspan="1">33</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Friedrichsen 2020 [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">36</td>
<td align="left" colspan="1" rowspan="1">36</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Garvey 2022 [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">152</td>
<td align="left" colspan="1" rowspan="1">152</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Granhall 2019 (T2DM) [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral daily</td>
<td align="left" colspan="1" rowspan="1">40 mg</td>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Heise 2022 [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]
</td>
<td align="left" colspan="1" rowspan="1">Eli Lilly</td>
<td align="left" colspan="1" rowspan="1">T2DM and overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">44</td>
<td align="left" colspan="1" rowspan="1">28</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Husain 2019 [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral daily</td>
<td align="left" colspan="1" rowspan="1">14 mg</td>
<td align="left" colspan="1" rowspan="1">1591</td>
<td align="left" colspan="1" rowspan="1">1592</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Kadowaki 2022 [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1.7 and 2.4 mg</td>
<td align="left" colspan="1" rowspan="1">300</td>
<td align="left" colspan="1" rowspan="1">101</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Kapitza 2017 [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">37</td>
<td align="left" colspan="1" rowspan="1">38</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Knop 2023 [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Oral daily</td>
<td align="left" colspan="1" rowspan="1">50 mg</td>
<td align="left" colspan="1" rowspan="1">334</td>
<td align="left" colspan="1" rowspan="1">333</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Kosiborod 2023 [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight and HFpEF</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">263</td>
<td align="left" colspan="1" rowspan="1">266</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Kosiborod 2024 [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight, T2DM and HFpEF</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">310</td>
<td align="left" colspan="1" rowspan="1">306</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Lincoff 2023 [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">8803</td>
<td align="left" colspan="1" rowspan="1">8801</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Lingvay 2018 [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous daily</td>
<td align="left" colspan="1" rowspan="1">0.05, 0.1, 0.2, and 0.3 mg</td>
<td align="left" colspan="1" rowspan="1">320</td>
<td align="left" colspan="1" rowspan="1">129</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Loomba 2023 [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">47</td>
<td align="left" colspan="1" rowspan="1">24</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Marso 2016 [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">0.5 and 1 mg</td>
<td align="left" colspan="1" rowspan="1">1648</td>
<td align="left" colspan="1" rowspan="1">1649</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mosenzon 2019 [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM and CKD</td>
<td align="left" colspan="1" rowspan="1">Oral daily</td>
<td align="left" colspan="1" rowspan="1">14 mg</td>
<td align="left" colspan="1" rowspan="1">163</td>
<td align="left" colspan="1" rowspan="1">161</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mu 2024 [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">249</td>
<td align="left" colspan="1" rowspan="1">126</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Nauck 2016 [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">0.1, 0.2, 0.4, 0.8, and 1.6 mg</td>
<td align="left" colspan="1" rowspan="1">274</td>
<td align="left" colspan="1" rowspan="1">46</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Newsome 2020 [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous daily</td>
<td align="left" colspan="1" rowspan="1">0.1, 0.2 and 0.4 mg</td>
<td align="left" colspan="1" rowspan="1">240</td>
<td align="left" colspan="1" rowspan="1">80</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">O’Neil 2018 [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>]</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous daily</td>
<td align="left" colspan="1" rowspan="1">0.05, 0.1, 0.2, and 0.4 mg</td>
<td align="left" colspan="1" rowspan="1">718</td>
<td align="left" colspan="1" rowspan="1">136</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Perkovic 2024 [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM and CKD</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">1767</td>
<td align="left" colspan="1" rowspan="1">1766</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Pratley 2019 [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral daily</td>
<td align="left" colspan="1" rowspan="1">14 mg</td>
<td align="left" colspan="1" rowspan="1">285</td>
<td align="left" colspan="1" rowspan="1">142</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Rodbard 2018 [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">0.5 and 1 mg</td>
<td align="left" colspan="1" rowspan="1">264</td>
<td align="left" colspan="1" rowspan="1">133</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Rubino 2022 [<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">126</td>
<td align="left" colspan="1" rowspan="1">85</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Sorli 2017 [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">0.5 and 1 mg</td>
<td align="left" colspan="1" rowspan="1">259</td>
<td align="left" colspan="1" rowspan="1">129</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Wadden 2021 [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">407</td>
<td align="left" colspan="1" rowspan="1">204</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Weghuber 2022 [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight (adolescents)</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">134</td>
<td align="left" colspan="1" rowspan="1">67</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Wilding 2021 [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">1306</td>
<td align="left" colspan="1" rowspan="1">655</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yamada 2020 [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral daily</td>
<td align="left" colspan="1" rowspan="1">3, 7, and 14 mg</td>
<td align="left" colspan="1" rowspan="1">146</td>
<td align="left" colspan="1" rowspan="1">49</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zinman March 2019 [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">151</td>
<td align="left" colspan="1" rowspan="1">151</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zinman May 2019 [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral daily</td>
<td align="left" colspan="1" rowspan="1">3, 7, and 14 mg</td>
<td align="left" colspan="1" rowspan="1">547</td>
<td align="left" colspan="1" rowspan="1">184</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Wang 2024 [<a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral daily</td>
<td align="left" colspan="1" rowspan="1">3, 7, and 14 mg</td>
<td align="left" colspan="1" rowspan="1">390</td>
<td align="left" colspan="1" rowspan="1">131</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<a href="https://clinicaltrials.gov/ct2/show/NCT04741074" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04741074</a> [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>]</td>
<td align="left" colspan="1" rowspan="1">Geisinger Clinic</td>
<td align="left" colspan="1" rowspan="1">T2DM and CKD</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">7</td>
<td align="left" colspan="1" rowspan="1">8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EUCTR2020-004863–14 [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>]</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM and overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">75</td>
<td align="left" colspan="1" rowspan="1">61</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Selvarajah 2024 [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]
</td>
<td align="left" colspan="1" rowspan="1">Astra Zeneca</td>
<td align="left" colspan="1" rowspan="1">T2DM and CKD</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">45</td>
<td align="left" colspan="1" rowspan="1">51</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> McGowan 2024 [<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">138</td>
<td align="left" colspan="1" rowspan="1">69</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Bliddal 2024 [<a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">271</td>
<td align="left" colspan="1" rowspan="1">136</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Sivalingam 2024 [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">30</td>
<td align="left" colspan="1" rowspan="1">30</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Apperloo 2024 [<a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM and CKD</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">51</td>
<td align="left" colspan="1" rowspan="1">50</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Gabe 2024 [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">Overweight</td>
<td align="left" colspan="1" rowspan="1">Oral</td>
<td align="left" colspan="1" rowspan="1">50 mg</td>
<td align="left" colspan="1" rowspan="1">30</td>
<td align="left" colspan="1" rowspan="1">31</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<a href="https://clinicaltrials.gov/ct2/show/NCT05486065" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05486065</a> [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>]</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM and overweight</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2, 8, and 16 mg</td>
<td align="left" colspan="1" rowspan="1">185</td>
<td align="left" colspan="1" rowspan="1">60</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Amin 2025 [<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>]
</td>
<td align="left" colspan="1" rowspan="1">Pfizer Inc</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral</td>
<td align="left" colspan="1" rowspan="1">14 mg</td>
<td align="left" colspan="1" rowspan="1">73</td>
<td align="left" colspan="1" rowspan="1">75</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Eckard 2024 [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>]
</td>
<td align="left" colspan="1" rowspan="1">National Institutes of Health</td>
<td align="left" colspan="1" rowspan="1">Overweight and HIV-1</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">54</td>
<td align="left" colspan="1" rowspan="1">54</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> McGuire 2025 [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Oral</td>
<td align="left" colspan="1" rowspan="1">14 mg</td>
<td align="left" colspan="1" rowspan="1">4825</td>
<td align="left" colspan="1" rowspan="1">4825</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Sanyal 2025 [<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">MASH</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">2.4 mg</td>
<td align="left" colspan="1" rowspan="1">802</td>
<td align="left" colspan="1" rowspan="1">395</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Bonaca 2025 [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]
</td>
<td align="left" colspan="1" rowspan="1">Novo Nordisk</td>
<td align="left" colspan="1" rowspan="1">T2DM</td>
<td align="left" colspan="1" rowspan="1">Subcutaneous weekly</td>
<td align="left" colspan="1" rowspan="1">1 mg</td>
<td align="left" colspan="1" rowspan="1">396</td>
<td align="left" colspan="1" rowspan="1">396</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p26"><p><em>T2DM</em> type 2 diabetes mellitus, <em>HFpEF</em> heart failure with preserved ejection fraction, <em>CKD</em> chronic kidney disease, <em>HIV-1</em> human immunodeficiency virus-1, <em>MASH</em> metabolic-associated steatohepatitis, <em>mg</em> milligram</p></div></div></section></section><section id="Sec7"><h3 class="pmc_sec_title">All-cause mortality</h3>
<p id="Par48">All-cause mortality was reported as an outcome in 48 trials [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>–<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>–<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>, <a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>–<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. Twenty-six trials reported no deaths in either of the compared groups [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>, <a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>, <a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>, <a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>, <a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>, <a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>, <a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>–<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>–<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>, <a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>, <a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>–<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>]. A total of 1249/30166 (4.1%) semaglutide participants died compared with 1454/24597 (5.9%) placebo participants. Meta-analysis showed evidence of a beneficial effect of semaglutide (RR 0.85, 95% CI 0.79 to 0.91; <em>I</em> [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>] = 0.0%; <em>p</em> &lt; 0.01; 22 trials; high certainty of evidence) (Fig. <a href="#Fig2" class="usa-link">2</a> and Additional file 1: Figure S2). Visual inspection of the forest plot and statistical test (<em>I</em><sup>2</sup> = 0.0%) indicated no heterogeneity. Trial Sequential Analysis (TSA) showed that the meta-analysis was sufficiently powered (Additional file 1: Figure S3). Beta-binomial regression, including the 25 trials with zero events in both groups, also showed evidence of a beneficial effect of semaglutide (odds ratio (OR) 0.84, 95% CI 0.77 to 0.91; <em>p</em>&lt; 0.01; 48 trials) (Additional file 1: Figure S4). The assessment time points were 15.5 weeks [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>], 17 weeks [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>, <a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>], 21 weeks [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>], 25 weeks [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>], 26 weeks [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>], 28 weeks [<a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>, <a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>], 30 weeks [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>], 31 weeks [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>], 32 weeks [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>], 33 weeks [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>], 36 weeks [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>, <a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>], 39 weeks [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>, <a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>], 49 weeks [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>], 51 weeks [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>], 55 weeks [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>], 57 weeks [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>, <a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>, <a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>], 59 weeks [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>], 72 weeks [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>], 75 weeks [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>, <a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>–<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>, <a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>], 79 weeks [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>], 87 weeks [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>], 109 weeks [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>], 111 weeks [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], 39.8 months (mean) [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>], 3.4 years (mean) [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>], and 47.5 months (mean) [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>] after randomization. This outcome result was assessed at low risk of bias, and the certainty of the evidence was high (Additional file 1: Table S1 and S2).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12642075_12916_2025_4486_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89a2/12642075/b2bf1775aca4/12916_2025_4486_Fig2_HTML.jpg" loading="lazy" id="MO2" height="730" width="778" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Fixed-effect meta-analysis of the relative risk of all-cause mortality with semaglutide versus placebo. I<sup>2</sup> is a statistical value for assessing heterogeneity. A value of <em>I</em><sup>2</sup> = 0% indicates no heterogeneity</p></figcaption></figure><p id="Par49">The predefined subgroup analyses comparing different patient groups and routes of administration showed no evidence of a difference (Additional file 1: Figure S5-8). The predefined subgroup analyses comparing doses of semaglutide at or above the median compared to below (oral and subcutaneous weekly), comparing different levels of treatment compliance, and comparing trials at risk of for-profit bias to trials at no for-profit bias risk were not performed due to a lack of relevant data. None of the remaining predefined subgroup analyses showed evidence of a difference (Additional file 1: Figure S9-14). Post hoc meta-regression showed no evidence of an association between the effect estimate and either age or body mass index (Additional file 1: Figure S15).</p></section><section id="Sec8"><h3 class="pmc_sec_title">Serious adverse events</h3>
<p id="Par50">Serious adverse events were reported as outcomes in 50 trials [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>–<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. One trial reported no serious adverse event in either of the compared groups [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>]. A total of 8017/30256 (26.5%) semaglutide participants had a serious adverse event compared with 8182/24686 (33.1%) placebo participants. Meta-analysis showed evidence of a beneficial effect of semaglutide (RR 0.93, 95% CI 0.88 to 0.98; <em>I</em><sup>2</sup> = 24.1%; <em>p</em> &lt; 0.01, 49 trials, high certainty of evidence) (Fig. <a href="#Fig3" class="usa-link">3</a> and Additional file 1: Figure S16-17). Visual inspection of the forest plot and statistical test (<em>I</em><sup>2</sup>= 24.1%) indicated moderate heterogeneity. TSA showed that the meta-analysis was sufficiently powered (Additional file 1: Figure S18). The assessment points were 15.5 weeks [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>], 17 weeks [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>, <a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>], 20 weeks [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>], 21 weeks [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>], 25 weeks [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>], 26 weeks [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>], 28 weeks [<a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>, <a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>], 30 weeks [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>], 31 weeks [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>], 32 weeks [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>], 33 weeks [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>], 36 weeks [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>, <a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>], 39 weeks [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>, <a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>], 49 weeks [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>], 51 weeks [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>], 52 weeks [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>], 55 weeks [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>], 56 weeks [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>], 57 weeks [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>, <a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>], 59 weeks [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>], 72 weeks [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>], 75 weeks [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>, <a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>–<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>, <a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>], 79 weeks [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>], 87 weeks [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>], 109 weeks [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>], 111 weeks [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], 39.8 months (mean) [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>], 3.4 years (mean) [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>], and 47.5 months (mean) [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>] after randomization. This outcome result was assessed at low risk of bias, and the certainty of the evidence was high (Additional file 1: Table S1 and S2).</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12642075_12916_2025_4486_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89a2/12642075/74759b898df3/12916_2025_4486_Fig3_HTML.jpg" loading="lazy" id="MO3" height="1239" width="737" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Random-effects meta-analysis of the relative risk of serious adverse events with semaglutide versus placebo. <em>I</em><sup>2</sup> is a statistical value for assessing heterogeneity. A value of <em>I</em><sup>2</sup> = 24.1% indicates moderate heterogeneity. T2DM, type 2 diabetes mellitus</p></figcaption></figure><p id="Par51">Subgroup analyses and post-hoc meta-regression can be found in Additional file 1: Supplementary Results and Additional file 1: Figure S19-33.</p>
<p id="Par52">When each specific serious adverse event was analyzed separately, 1/281 meta-analyses showed evidence of a harmful effect of semaglutide on: diarrhea (RR 1.76; 95% CI 1.10 to 2.80; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.02; 11 trials; number needed to harm (NNH): 666) (Additional file 1: Figure S34-35).</p>
<p id="Par53">Eight of 281 meta-analyses showed evidence of a beneficial effect of semaglutide on: acute myocardial infarction (RR 0.73; 95% CI 0.63 to 0.84; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01; 17 trials; number needed to treat (NNT): 113) (Additional file 1: Figure S36-37), pneumonia (RR 0.76; 95% CI 0.64 to 0.91; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01; 17 trials; NNT: 177) (Additional file 1: Figure S38-39), percutaneous coronary intervention (RR 0.59; 95% CI 0.45 to 0.79; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01; 3 trials; NNT: 200) (Additional file 1: Figure S40-41), covid-19 pneumonia (RR 0.79; 95% CI 0.65 to 0.96; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.02; 7 trials; NNT: 246) (Additional file 1: Figure S42-43), angina pectoris (RR 0.77; 95% CI 0.63 to 0.95; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.01; 12 trials; NNT: 273) (Additional file 1: Figure S44-45), cellulitis (RR 0.66; 95% CI 0.48 to 0.90; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.01; 12 trials; NNT: 436) (Additional file 1: Figure S46-47), diabetes mellitus inadequate control (RR 0.37; 95% CI 0.16 to 0.84; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.02; 6 trials; NNT: 1120) (Additional file 1: Figure S48-49), and asthma (RR 0.40; 95% CI 0.18 to 0.89; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.02; 7 trials; NNT: 1134) (Additional file 1: Figure S50-51).</p>
<p id="Par54">The remaining 272 meta-analyses showed no evidence of differences (Additional file 1: Figure S52-99; Additional file 2: Figure S100-285; Additional file 3: Figure S286-471; Additional file 4: Figure S472-595).</p></section><section id="Sec9"><h3 class="pmc_sec_title">Myocardial infarction</h3>
<p id="Par55">Myocardial infarction was reported as an outcome in 33 trials [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>, <a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>–<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>, <a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>, <a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>, <a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>–<a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>, <a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>, <a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>, <a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>, <a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. Eleven trials reported no events of myocardial infarction in either of the compared groups [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>, <a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>, <a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>, <a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>, <a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>, <a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]. A total of 595/28161 (2.1%) semaglutide participants had myocardial infarction compared with 761/23286 (3.3%) placebo participants. Meta-analysis showed evidence of a beneficial effect of semaglutide (RR 0.77, 95% CI 0.69 to 0.85; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01; 22 trials; high certainty of evidence) (Additional file 4: Figure S596-597). Visual inspection of the forest plot and statistical test (<em>I</em><sup>2</sup> = 0.0%) indicated no heterogeneity. TSA showed that the meta-analysis was sufficiently powered (Additional file 4: Figure S598). Beta-binomial regression, including the 11 trials with zero events in both groups, also showed evidence of a beneficial effect of semaglutide (OR 0.76, 95% CI 0.68 to 0.85; <em>p</em>&lt; 0.001; 33 trials) (Additional file 4: Figure S599). The assessment time points were 17 weeks [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>], 30 weeks [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>], 31 weeks [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>], 32 weeks [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>], 33 weeks [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>], 36 weeks [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>, <a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>], 51 weeks [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>], 52 weeks [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>], 57 weeks [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>], 59 weeks [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>], 75 weeks [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>, <a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>–<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>], 79 weeks [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>], 87 weeks [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>], 109 weeks [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>], 111 weeks [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], 39.8 months (mean) [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>], 3.4 years (mean) [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>], and 47.5 months (mean) [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>] after randomization. This outcome result was assessed at low risk of bias, and the certainty of the evidence was high (Additional file 1: Table S1 and S2).</p>
<p id="Par56">Subgroup analyses can be found in Additional file 4: Figure S600-611.</p></section><section id="Sec10"><h3 class="pmc_sec_title">Stroke</h3>
<p id="Par57">Stroke was reported as an outcome in 29 trials [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>, <a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>, <a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>, <a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>–<a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>, <a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>, <a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>]. Ten trials reported no events of stroke in either of the compared groups [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>, <a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>, <a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>, <a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]. A total of 433/27249 (1.6%) semaglutide participants had stroke compared with 455/22461 (2.0%) placebo participants. Meta-analysis showed no evidence of a difference (RR 0.93, 95% CI 0.82 to 1.06; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.27; 19 trials; moderate certainty of evidence) (Additional file 4: Figure S612-613). Visual inspection of the forest plot and statistical test (<em>I</em><sup>2</sup> = 0.0%) indicated no statistical heterogeneity. TSA showed that the meta-analysis was sufficiently powered (Additional file 4: Figure S614). Beta-binomial regression, including the ten trials with zero events in both groups, also showed no evidence of a difference (OR 0.93, 95% CI 0.82 to 1.07; <em>p</em>= 0.31; 29 trials) (Additional file 4: Figure S615). The assessment time points were 17 weeks [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>], 30 weeks [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>], 31 weeks [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>], 33 weeks [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>], 36 weeks [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>, <a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>], 51 weeks [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>], 52 weeks [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>], 57 weeks [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>], 59 weeks [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>], 75 weeks [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>, <a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>–<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>], 79 weeks [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>], 87 weeks [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>], 109 weeks [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>], 111 weeks [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], 39.8 months (mean) [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>], 3.4 years (mean) [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>], and 47.5 months (mean) [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>] after randomization. This outcome result was assessed at low risk of bias, and the certainty of the evidence was moderate (Additional file 1: Table S1 and S2).</p></section><section id="Sec11"><h3 class="pmc_sec_title">All-cause hospitalization</h3>
<p id="Par58">All-cause hospitalization was reported as an outcome in four trials [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>, <a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>, <a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>, <a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>]. A total of 263/16867 (1.6%) semaglutide participants were hospitalized compared with 282/16867 (1.7%) placebo participants. Meta-analysis showed no evidence of a difference (RR 0.93, 95% CI 0.79 to 1.10; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.42; 4 trials; low certainty of evidence) (Additional file 4: Figure S616-617). Visual inspection of the forest plot and statistical test (<em>I</em><sup>2</sup>= 0.0%) indicated no heterogeneity. TSA showed that the meta-analysis was sufficiently powered (Additional file 4: Figure S618). The assessment time points were 87 weeks [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>], 109 weeks [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>], 39.8 months (mean) [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>], and 47.5 months (mean) [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>] after randomization. This outcome result was assessed at low risk of bias, and the certainty of the evidence was low (Additional file 1: Table S1 and S2).</p></section><section id="Sec12"><h3 class="pmc_sec_title">Non-serious adverse events</h3>
<p id="Par59">Non-serious adverse events were reported as outcomes in 45 trials [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>–<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>–<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>–<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>, <a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>–<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>–<a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>, <a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>–<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>, <a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>, <a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. A total of 12,483/21733 (57.4%) semaglutide participants had one or more non-serious adverse events compared with 6491/16159 (40.2%) placebo participants (Additional file 5: Figure S619-621). The assessment points were 15.5 weeks [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>], 17 weeks [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>, <a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>], 20 weeks [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>], 21 weeks [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>], 25 weeks [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>], 28 weeks [<a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>, <a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>], 30 weeks [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>], 31 weeks [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>], 32 weeks [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>], 33 weeks [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>], 36 weeks [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>, <a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>], 39 weeks [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>, <a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>], 48 weeks [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>], 49 weeks [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>], 51 weeks [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>], 52 weeks [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>], 56 weeks [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>], 57 weeks [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>], 59 weeks [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>], 72 weeks [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>], 75 weeks [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>, <a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>–<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>, <a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>], 79 weeks [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>], 109 weeks [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>], 111 weeks [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], and 39.8 months (mean) [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>] after randomization. This outcome result was assessed at low risk of bias, and the certainty of the evidence was moderate (Additional file 1: Table S1 and S2).</p>
<p id="Par60">When each specific non-serious adverse event was analyzed separately, 20/49 meta-analyses showed evidence of a harmful effect of semaglutide on: nausea (RR 3.00; 95% CI 2.63 to 3.42; <em>I</em><sup>2</sup> = 59.9%; <em>p</em> &lt; 0.01, 43 trials; NNH: 6) (Additional file 5: Figure S622-623), vomiting (RR 4.12; 95% CI 3.47 to 4.90; <em>I</em><sup>2</sup> = 32.1%;<em> p</em> &lt; 0.01, 40 trials; NNH: 11) (Additional file 5: Figure S624-625), diarrhea (RR 1.88; 95% CI 1.68 to 2.11; <em>I</em><sup>2</sup> = 42.5%; <em>p</em> &lt; 0.01, 43 trials; NNH: 11) (Additional file 5: Figure S626-627), constipation (RR 2.35; 95% CI 2.03 to 2.72; <em>I</em><sup>2</sup> = 39.3%; <em>p</em> &lt; 0.01, 36 trials; NNH: 13) (Additional file 5: Figure S628-629), decreased appetite (RR 3.66; 95% CI 3.03 to 4.43; <em>I</em><sup>2</sup> = 27.8%; <em>p</em> &lt; 0.01, 33 trials; NNH: 14) (Additional file 5: Figure S630-631), eructation (RR 5.92; 95% CI 4.02 to 8.70; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01, 18 trials; NNH: 15) (Additional file 5: Figure S632-633), dyspepsia (RR 3.11; 95% CI 2.55 to 3.79; <em>I</em><sup>2</sup> = 21.1%; <em>p</em> &lt; 0.01, 30 trials; NNH: 19) (Additional file 5: Figure S634-635), asthenia (RR 4.23; 95% CI 1.34 to 13.36; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.01, 4 trials; NNH: 24) (Additional file 5: Figure S636-637), gastroesophageal reflux disease (RR 2.86; 95% CI 2.17 to 3.76; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01, 17 trials; NNH: 24) (Additional file 5: Figure S638-639), abdominal pain (RR 1.90; 95% CI 1.50 to 2.42; <em>I</em><sup>2</sup> = 24.1%; <em>p</em> &lt; 0.01, 22 trials; NNH: 30) (Additional file 5: Figure S640-641), abdominal pain upper (RR 1.72; 95% CI 1.41 to 2.09; <em>I</em><sup>2</sup> = 8.1%; <em>p</em> &lt; 0.01, 20 trials; NNH: 33) (Additional file 5: Figure S642-643), fatigue (RR 1.67; 95% CI 1.41 to 1.97; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01, 22 trials; NNH: 35) (Additional file 5: Figure S644-645), abdominal discomfort (RR 2.17; 95% CI 1.24 to 3.79; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01, 9 trials; NNH: 38) (Additional file 5: Figure S646-647), gastroenteritis (RR 1.77; 95% CI 1.35 to 2.32; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01, 11 trials; NNH: 45) (Additional file 5: Figure S648-649), dizziness (RR 1.49; 95% CI 1.18 to 1.87; <em>I</em><sup>2</sup> = 21.6%; <em>p</em> &lt; 0.01, 25 trials; NNH: 48) (Additional file 5: Figure S650-651), flatulence (RR 1.47; 95% CI 1.12 to 1.95; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.01, 12 trials; NNH: 52) (Additional file 5: Figure S652-653), abdominal distension (RR 1.48; 95% CI 1.16 to 1.88; <em>I</em><sup>2</sup> = 16.6%; <em>p</em> &lt; 0.01, 19 trials; NNH: 48) (Additional file 5: Figure S654-655), headache (RR 1.19; 95% CI 1.05 to 1.36; <em>I</em><sup>2</sup> = 13.7%; <em>p</em> = 0.01, 31 trials; NNH: 60) (Additional file 5: Figure S656-657), alopecia (RR 2.36; 95% CI 1.20 to 4.61; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.01, 4 trials; NNH: 61) (Additional file 5: Figure S658-659), and lipase increased (RR 1.53; 95% CI 1.26 to 1.86; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01, 13 trials; NNH: 104) (Additional file 5: Figure S660-661),</p>
<p id="Par61">In total, 5/49 meta-analyses showed evidence of a beneficial effect of semaglutide: hyperglycemia (RR 0.25; 95% CI 0.12 to 0.52; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> &lt; 0.01; 5 trials; NNT: 14) (Additional file 5: Figure S662-663), contusion (RR 0.38; 95% CI 0.18 to 0.82; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.01; 2 trials; NNT: 27) (Additional file 5: Figure S664-665), hypertension (RR 0.53; 95% CI 0.31 to 0.88; <em>I</em><sup>2</sup> = 36.7%; <em>p</em> = 0.02; 9 trials; NNT: 34) (Additional file 5: Figure S666-667), cough (RR 0.74; 95% CI 0.59 to 0.93; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.01; 8 trials; NNT: 63) (Additional file 5: Figure S668-669), and upper respiratory tract infection (RR 0.88; 95% CI 0.78 to 0.98; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.02; 22 trials; NNT: 92) (Additional file 5: Figure S670-671).</p>
<p id="Par62">The remaining 24 meta-analyses showed no evidence of differences (Additional file 5: Figure S672-719).</p>
<p id="Par63">Meta-analyses of the predefined exploratory outcomes can be found in Additional file 1: Supplementary Results and Additional file 5: Figure S720-738. Additional post-hoc subgroup analyses can be found in Additional file 6: Figure S739-744.</p>
<p id="Par64">We performed an additional meta-analysis of the adverse event, ischemic anterior neuropathy. A total of 5/10451 (0.0004%) semaglutide participants had this event compared with 1/10450 (0.0001%) placebo participants. Meta-analysis showed no significant difference (RR 2.85, 95% CI 0.43 to 18.70; <em>I</em><sup>2</sup> = 0.0%; <em>p</em> = 0.28; 2 trials) (Additional file 6: Figure S745–746).</p></section><section id="Sec13"><h3 class="pmc_sec_title">Publication bias</h3>
<p id="Par65">Funnel plots showed no evidence of asymmetry for all-cause mortality, serious adverse events, myocardial infarction, or stroke, suggesting a low risk of publication bias for these outcomes. This was supported by Egger’s test, which did not indicate significant publication bias (Additional file 6: Figure S747-762). In contrast, for non-serious adverse events, the funnel plot appeared symmetrical, but Egger’s test suggested potential publication bias (<em>p</em> = 0.002) (Additional file 6: Figure S763-765). Nevertheless, given the wide range of reported adverse effects, heterogeneity is likely to be present.</p></section></section><section id="Sec14"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par66">We conducted a systematic review assessing the adverse effects associated with semaglutide use compared with placebo in patients at increased risk of cardiovascular events. A total of 50 placebo-controlled trials randomizing 54,972 participants were included. Meta-analysis and TSA showed that semaglutide reduced the risks of death and myocardial infarction in patients at increased risk of cardiovascular events. Meta-analysis and TSA showed that semaglutide lowered the incidence of serious adverse events, although it increased the risks of several non-serious gastrointestinal adverse events. The non-serious adverse events with the lowest NNH were nausea, vomiting, diarrhea, constipation, and eructation. Some of the NNTs and NNHs for individual adverse events were generally high, suggesting low absolute risks and limited clinical relevance despite statistical significance. The remaining analyses of secondary outcomes (i.e., stroke and all-cause hospitalization) showed no evidence of differences.</p>
<p id="Par67">Previous systematic reviews have assessed the adverse effects associated with semaglutide use; however, these reviews were limited to specific disease groups (e.g., only type 2 diabetes) or restricted to administration form (e.g., oral administration) [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>–<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>, <a href="#CR129" class="usa-link" aria-describedby="CR129">129</a>].All of these previous systematic reviews have found that semaglutide increases the risk of gastrointestinal adverse events. One systematic review assessed the effects of semaglutide on cardiovascular outcomes, but only in patients with obesity or overweight [<a href="#CR130" class="usa-link" aria-describedby="CR130">130</a>]. This review found that semaglutide reduced the risk of all-cause mortality (21% reduction) and non-fatal myocardial infarction (24% reduction), but increased the risk of gastrointestinal adverse events. However, this particular review did not systematically assess other adverse effects, only included 16 trials compared to 50 trials in the present review, and did not control the risks of random errors using TSA.</p>
<section id="Sec15"><h3 class="pmc_sec_title">Strengths and limitations</h3>
<p id="Par68">Our systematic review has multiple strengths. It is the first to systematically assess the adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events. The predefined methodology was based on PRISMA [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>], our eight-step procedure by Jakobsen et al., [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>] TSA [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>], and GRADE assessments [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. The comprehensive literature search, combined with the inclusion of a large number of trials, has increased the robustness of the review. The meta-analyses of mortality and myocardial infarction showed no signs of heterogeneity, enhancing our confidence in the validity of our findings. We increased the statistical power by including all trials that enrolled patients at increased risk of cardiovascular events.</p>
<p id="Par69">Our systematic review also has limitations. First, some of the included trials had short maximum follow-up time points (down to 15.5 weeks), while some of the larger trials had longer maximum follow-up time points (up to 47.5 months (mean)). Although we did not identify signs of heterogeneity in most analyses, these short and varying observation trial periods should be considered when interpreting our results. Meta-regression of SAEs revealed that age and body mass index may account for some of the observed heterogeneity. Second, we planned multiple outcome comparisons and adjusted our thresholds for significance according to the number of primary outcomes to control the risk of random errors. However, we did not adjust the thresholds for significance according to the total number of comparisons (i.e., secondary outcomes, exploratory outcomes, subgroup analyses, and sensitivity analyses). Third, given the large number of specific serious adverse events reported in some trials (up to over 1700 different serious adverse events in one trial) [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>], we opted to meta-analyze serious adverse event data only if at least one trial in either the intervention or placebo group reported five or more events. This pragmatic choice was made to avoid conducting up to a thousand different meta-analyses that would not provide meaningful insights into the effects of semaglutide. However, this may lead to under-reporting of individual serious adverse events. Fourth, 27 out of 50 trials (54%) were assessed at high risk of bias. Although 84.4% of the participants were from trials at low risk of bias, the high risk of bias trials may have influenced the results. Finally, 44/50 (88%) of the included trials were supported by Novo Nordisk, the developer and producer of semaglutide. Due to the high quality of trial methodology, design, and adequate reporting, we did not downgrade the evidence due to the potential of for-profit bias. Nonetheless, Novo Nordisk’s support should be considered when interpreting our results.</p></section><section id="Sec16"><h3 class="pmc_sec_title">Implications and future research</h3>
<p id="Par70">Gastrointestinal adverse effects of semaglutide, such as nausea, vomiting and diarrhea, may partly be explained by delayed gastric emptying and other gastrointestinal mechanisms [<a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>]. These effects and adverse effects can contribute to reduced quality of life, and for some, lead to dose reduction or discontinuation [<a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>]. An improved understanding of these mechanisms, along with patient education on their effects, may support better patient counselling and treatment adherence.</p>
<p id="Par71">Recently, a retrospective observational study [<a href="#CR132" class="usa-link" aria-describedby="CR132">132</a>] found a possible association between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION). Among the 50 trials reviewed, only two trials [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>, <a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>] reported participants with ischemic optic neuropathy, and meta-analysis showed no significant difference between semaglutide and placebo. Consequently, our findings do not support the presence of a significant risk of semaglutide causing such harm.</p>
<p id="Par72">We conclude that semaglutide’s beneficial effects on mortality and myocardial infarction were observed in the included populations and administration routes. However, caution is warranted in interpreting heterogeneity tests and subgroup comparisons, as they essentially involve non-randomized comparisons. Given the impracticality of randomizing patients across different diseases, improving our analyses to compare semaglutide’s effects across patient groups presents a challenge. We identified only one previous trial [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>] (<em>N</em> = 491) that has explored different doses of oral semaglutide compared with an open-label arm of 1 mg subcutaneous semaglutide (<em>N</em> = 70). The trial did not report evidence of a difference between oral and subcutaneous semaglutide on mortality or myocardial infarction. Future trials examining different routes of semaglutide administration (e.g., oral versus subcutaneous administration) are essential to validate or refute our findings regarding potential differential effects.</p></section></section><section id="Sec17"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par73">In patients at increased risk of cardiovascular events, semaglutide use is associated with a reduced risk of mortality, serious adverse events, and myocardial infarction. Additionally, semaglutide use is associated with an increased risk of several gastrointestinal adverse events.</p></section><section id="Sec240"><h2 class="pmc_sec_title">Supplementary Information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM1_ESM.docx</a><sup> (18.9MB, docx) </sup><p>Additional file 1. Supplementary methods and results, list of excluded trials, search strategies, Tables S1-2, Figure S1-99. Figure S1—PRISMA checklist. Figure S2—Forest plot of all-cause mortality. Figure S3—TSA of all-cause mortality. Figure S4—Beta-binomial regression of all-cause mortality. Figure S5-S14—Subgroup analyses of all-cause mortality. Figure S15—Meta-regression of all-cause mortality. Figure S16—Forest plot of serious adverse events. Figure S17—Beta-binomial regression of serious adverse events. Figure S18—TSA of serious adverse events. Figure S19-32 – Subgroup analyses of serious adverse events. Figure S33 – Meta-regression of serious adverse events. Figure S34-35 – Forest plots of harmful individual SAEs. Figure S36-51 – Forest plots of beneficial SAEs. Figure S52-99 – Forest plot of individual SAEs showing no signs of a difference.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM2_ESM.docx</a><sup> (19MB, docx) </sup><p>Additional file 2. Figure S100-285 - Forest plot of individual SAEs showing no signs of a difference.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM3"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM3_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM3_ESM.docx</a><sup> (18.9MB, docx) </sup><p>Additional file 3. Figure S286-471. Figure S286-471 - Forest plot of individual SAEs showing no signs of a difference.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM4"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM4_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM4_ESM.docx</a><sup> (17.5MB, docx) </sup><p>Additional file 4. Figure S472-618. Figure S472-595 - Forest plot of individual SAEs showing no signs of a difference. Figure S596-597 – Forest plots of myocardial infarction. Figure S598 – TSA of myocardial infarction. Figure S599 – Beta-binomial regression of myocardial infarction. Figure S600-611 – Subgroup analyses of myocardial infarction. Figure S612-613 – Forest plots of stroke. Figure S614 – TSA of stroke. Figure S615 – Beta-binomial regression of stroke. Figure S616-617 – Forest plots of all-cause hospitalization. Figure S618 – TSA of all-cause hospitalization.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM5"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM5_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM5_ESM.docx</a><sup> (18.8MB, docx) </sup><p>Additional file 5. Figure S619-620 – Forest plots of non-serious adverse events. Figure S621 – TSA of non-serious adverse events. Figure S622-661 – Forest plots of harmful individual non-serious adverse events. Figure S662-671 – Forest plots of beneficial individual non-serious adverse events. Figure S672-719 – Forest plots of individual non-serious adverse events showing no signs of a difference. Figure S720-721 – Forest plots of pancreatitis. Figure S722 – TSA of pancreatitis. Figure S723 – Beta S720-721 – Forest plots of pancreatitis. Figure S722 – TSA of pancreatitis. Figure S723 – Betabinomial regression of pancreatitis. Figure S724-725 – Forest plots of cancer. Figure S726 – TSA of cancer. Figure S727 – Beta-binomial regression of cancer. Figure S728-729 – Forest plots of suicide and suicide attempt. Figure S730 – TSA of suicide and suicide attempt. Figure S731 – Beta binomial regression of suicide and suicide attempt. Figure S732-733 – Forest plots of the composite outcome. Figure S734 – TSA of composite outcome. Figure S735-736 – Forest plots of vision change. Figure S737 – TSA of vision change. Figure S738 – Beta-binomial regression of vision change.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM6"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM6_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM6_ESM.docx</a><sup> (6MB, docx) </sup><p>Additional file 6. Figure S739-790. Figure S739-744 – Additional post-hoc subgroup analyses. Figure S745-746 – Post-hoc metaanalyses of ischemic anterior neuropathy. Figure S747-778 – Test for publication bias for all outcomes. Figure S779-790 – Post-hoc sensitivity analyses.</p>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>JJP, PF, DY, RKA, JLB, CKB, CG, and JCJ thank Copenhagen Trial Unit, Centre for Clinical Intervention Research, for employment. At the time of her contributions to this review, FS was employed with the Copenhagen Trial Unit, Centre for Clinical Intervention Research.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>AEs</dt>
<dd><p id="Par7">Adverse events</p></dd>
<dt>CI</dt>
<dd><p id="Par8">Confidence interval</p></dd>
<dt>CPCI-S</dt>
<dd><p id="Par9">Conference Proceedings Citation Index— Science</p></dd>
<dt>EMBASE</dt>
<dd><p id="Par10">Excerpta Medica database</p></dd>
<dt>GLP-1 RA</dt>
<dd><p id="Par11">Glucagon-like peptide-1 receptor agonist</p></dd>
<dt>GRADE</dt>
<dd><p id="Par12">Grading Recommendations Assessment Development Evaluation</p></dd>
<dt>HFpEF</dt>
<dd><p id="Par13">Heart failure with preserved ejection fraction</p></dd>
<dt>HIV-1</dt>
<dd><p id="Par14">Human immunodeficiency virus-1</p></dd>
<dt>ICH-GCP</dt>
<dd><p id="Par15">International Conference on Harmonisation-Good Clinical Practice</p></dd>
<dt>ITT</dt>
<dd><p id="Par16">Intention-to-treat</p></dd>
<dt>LILACS</dt>
<dd><p id="Par17">Latin American and Caribbean Health Sciences Literature</p></dd>
<dt>MASH</dt>
<dd><p id="Par18">Metabolic-associated steatohepatitis</p></dd>
<dt>MEDLINE</dt>
<dd><p id="Par19">Medical Literature Analysis and Retrieval System Online</p></dd>
<dt>NAION</dt>
<dd><p id="Par20">Non-arteritic anterior ischemic optic neuropathy</p></dd>
<dt>NNH</dt>
<dd><p id="Par21">Number needed to harm</p></dd>
<dt>NNT</dt>
<dd><p id="Par22">Number needed to treat</p></dd>
<dt>OR</dt>
<dd><p id="Par23">Odds ratio</p></dd>
<dt>PRISMA</dt>
<dd><p id="Par24">Preferred Reporting Items for Systematic Reviews and Meta-Analysis</p></dd>
<dt>RoB 2</dt>
<dd><p id="Par25">Cochrane Risk of Bias tool, version 2</p></dd>
<dt>RR</dt>
<dd><p id="Par26">Relative risk</p></dd>
<dt>SAEs</dt>
<dd><p id="Par27">Serious adverse events</p></dd>
<dt>SCI-EXPANDED</dt>
<dd><p id="Par28">Science Citation Index Expanded</p></dd>
<dt>TSA</dt>
<dd><p id="Par29">Trial Sequential Analysis</p></dd>
<dt>T2DM</dt>
<dd><p id="Par30">Type 2 diabetes mellitus</p></dd>
<dt>95% CI</dt>
<dd><p id="Par31">95% confidence interval</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Authors' contributions</h2>
<p>The study idea, design and conduct were conceived by CDBS and JCJ. CDBS authored the initial draft and worked closely with JCJ on crafting the first version of the manuscript. Subsequently, JJP, PF, DY, FS, RKA, LG, JLB, CBK, JG, HD, AF, PG, CG, and OM critically revised the manuscript and approved the submitted version. All authors read and approved the final manuscript. CDBS is the guarantor. CDBS, DY, LG, and RKA were responsible for literature screening. CDBS, JJP, PF, DY, FS, and JLB were responsible for data collection and risk of bias assessments. Statistical analyses were conducted by CDBS and JCJ. CDBS and JJP were responsible for GRADE assessments. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.</p>
<section id="FPar1"><h3 class="pmc_sec_title">Authors’ X handles</h3>
<p id="Par74">X handles: @JohannesGrand (Johannes Grand).</p></section></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>The dataset supporting the conclusions of this article is included within the article (and its additional file).
</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar2"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par75">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par76">Not applicable.</p></section><section id="FPar4"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par77">CDBS’s husband has previously been employed at Novo Nordisk, Kalundborg, as ‘facility manager’ and ‘sprinkler technician’ (employed from September 1, 2024, to August 31, 2025). PG has received lecture fees for Novo Nordisk, AstraZeneca, Eli Lilly, Bayer, and MSD and has served in Advisory Boards for Novo Nordisk, AstraZeneca, and Bayer. The remaining authors declare no known competing interests.
</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher's Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References
</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Lebrun LJ, Lenaerts K, Kiers D, et al. Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion. Cell Rep. 2017;21:1160–8. 10.1016/j.celrep.2017.10.008.
</cite> [<a href="https://doi.org/10.1016/j.celrep.2017.10.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29091756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lebrun%20LJ,%20Lenaerts%20K,%20Kiers%20D,%20et%20al.%20Enteroendocrine%20L%20cells%20sense%20LPS%20after%20gut%20barrier%20injury%20to%20enhance%20GLP-1%20secretion.%20Cell%20Rep.%202017;21:1160%E2%80%938.%2010.1016/j.celrep.2017.10.008." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Aaboe K, Krarup T, Madsbad S, Holst JJ. GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab. 2008;10:994–1003. 10.1111/j.1463-1326.2008.00853.x.
</cite> [<a href="https://doi.org/10.1111/j.1463-1326.2008.00853.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18435775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Aaboe%20K,%20Krarup%20T,%20Madsbad%20S,%20Holst%20JJ.%20GLP-1:%20physiological%20effects%20and%20potential%20therapeutic%20applications.%20Diabetes%20Obes%20Metab.%202008;10:994%E2%80%931003.%2010.1111/j.1463-1326.2008.00853.x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>FDA approves new drug treatment for chronic weight management, first since 2014. U.S. Food &amp; Drug Administration. 2021 Available from: <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014</a>.</cite>
</li>
<li id="CR4">
<span class="label">4.</span><cite>Ozempic® (semaglutide) approved in the US. Novo Nordisk. 2017 Available from: <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=712" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=712</a>.</cite>
</li>
<li id="CR5">
<span class="label">5.</span><cite>WEGOVY (semaglutide) injection, for subcutaneous use. U.S. Food and Drug Administration. 2021. Available from: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf</a>.</cite>
</li>
<li id="CR6">
<span class="label">6.</span><cite>FDA approves treatment for serious liver disease known as ‘MASH’. U.S. Food &amp; Drug Administration. 2025 Available from: <a href="https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash</a>.</cite>
</li>
<li id="CR7">
<span class="label">7.</span><cite>Hughes S, Neumiller JJ. Oral semaglutide. Clin Diabetes. 2020;38:109–11. 10.2337/cd19-0079.
</cite> [<a href="https://doi.org/10.2337/cd19-0079" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6969659/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31975761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hughes%20S,%20Neumiller%20JJ.%20Oral%20semaglutide.%20Clin%20Diabetes.%202020;38:109%E2%80%9311.%2010.2337/cd19-0079." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>FDA. OZEMPIC (semaglutide) injection, for subcutaneous use: U.S. Food &amp; Drug Administration. Available from: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s012lbl.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s012lbl.pdf</a>.</cite>
</li>
<li id="CR9">
<span class="label">9.</span><cite>Zaazouee MS, Hamdallah A, Helmy SK, et al. Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes Metab Syndr. 2022;16:102511. 10.1016/j.dsx.2022.102511.
</cite> [<a href="https://doi.org/10.1016/j.dsx.2022.102511" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35623229/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zaazouee%20MS,%20Hamdallah%20A,%20Helmy%20SK,%20et%20al.%20Semaglutide%20for%20the%20treatment%20of%20type%202%20diabetes%20mellitus:%20a%20systematic%20review%20and%20network%20meta-analysis%20of%20safety%20and%20efficacy%20outcomes.%20Diabetes%20Metab%20Syndr.%202022;16:102511.%2010.1016/j.dsx.2022.102511." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Zhang R, Hou QC, Li BH, et al. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1132004. 10.3389/fendo.2023.1132004.
</cite> [<a href="https://doi.org/10.3389/fendo.2023.1132004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10338217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37455913/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20R,%20Hou%20QC,%20Li%20BH,%20et%20al.%20Efficacy%20and%20safety%20of%20subcutaneous%20semaglutide%20in%20adults%20with%20overweight%20or%20obese:%20a%20subgroup%20meta-analysis%20of%20randomized%20controlled%20trials.%20Front%20Endocrinol%20(Lausanne).%202023;14:1132004.%2010.3389/fendo.2023.1132004." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Gao X, Hua X, Wang X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:935823. 10.3389/fphar.2022.935823.
</cite> [<a href="https://doi.org/10.3389/fphar.2022.935823" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9515581/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36188627/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gao%20X,%20Hua%20X,%20Wang%20X,%20et%20al.%20Efficacy%20and%20safety%20of%20semaglutide%20on%20weight%20loss%20in%20obese%20or%20overweight%20patients%20without%20diabetes:%20a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials.%20Front%20Pharmacol.%202022;13:935823.%2010.3389/fphar.2022.935823." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Iqbal J, Wu H-X, Hu N, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials. Obes Rev. 2022;23:e13435. 10.1111/obr.13435.
</cite> [<a href="https://doi.org/10.1111/obr.13435" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35194917/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Iqbal%20J,%20Wu%20H-X,%20Hu%20N,%20et%20al.%20Effect%20of%20glucagon-like%20peptide-1%20receptor%20agonists%20on%20body%20weight%20in%20adults%20with%20obesity%20without%20diabetes%20mellitus%E2%80%94a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20control%20trials.%20Obes%20Rev.%202022;23:e13435.%2010.1111/obr.13435." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Xie Z, Hu J, Gu H, Li M, Chen J. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. Front Endocrinol (Lausanne). 2023;14:1244432. 10.3389/fendo.2023.1244432.
</cite> [<a href="https://doi.org/10.3389/fendo.2023.1244432" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10493284/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37701904/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xie%20Z,%20Hu%20J,%20Gu%20H,%20Li%20M,%20Chen%20J.%20Comparison%20of%20the%20efficacy%20and%20safety%20of%2010%20glucagon-like%20peptide-1%20receptor%20agonists%20as%20add-on%20to%20metformin%20in%20patients%20with%20type%202%20diabetes:%20a%20systematic%20review.%20Front%20Endocrinol%20(Lausanne).%202023;14:1244432.%2010.3389/fendo.2023.1244432." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Iannone A, Natale P, Palmer SC, et al. Clinical outcomes associated with drugs for obesity and overweight: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023;25:2535–44. 10.1111/dom.15138.
</cite> [<a href="https://doi.org/10.1111/dom.15138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37254688/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Iannone%20A,%20Natale%20P,%20Palmer%20SC,%20et%20al.%20Clinical%20outcomes%20associated%20with%20drugs%20for%20obesity%20and%20overweight:%20a%20systematic%20review%20and%20network%20meta-analysis%20of%20randomized%20controlled%20trials.%20Diabetes%20Obes%20Metab.%202023;25:2535%E2%80%9344.%2010.1111/dom.15138." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Sillassen CDB, Kamp CB, Petersen JJ, et al. Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis. BMJ Open. 2024;14:e084190. 10.1136/bmjopen-2024-084190.
</cite> [<a href="https://doi.org/10.1136/bmjopen-2024-084190" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11331358/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38908837/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sillassen%20CDB,%20Kamp%20CB,%20Petersen%20JJ,%20et%20al.%20Adverse%20effects%20with%20semaglutide:%20a%20protocol%20for%20a%20systematic%20review%20with%20meta-analysis%20and%20trial%20sequential%20analysis.%20BMJ%20Open.%202024;14:e084190.%2010.1136/bmjopen-2024-084190." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Rivera F, Arias-Aguirre E, Aguirre Z, et al. Evaluating the safety profile of semaglutide: an updated meta-analysis. Curr Med Res Opin. 2024;40:1495–514. 10.1080/03007995.2024.2383731.
</cite> [<a href="https://doi.org/10.1080/03007995.2024.2383731" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39046272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rivera%20F,%20Arias-Aguirre%20E,%20Aguirre%20Z,%20et%20al.%20Evaluating%20the%20safety%20profile%20of%20semaglutide:%20an%20updated%20meta-analysis.%20Curr%20Med%20Res%20Opin.%202024;40:1495%E2%80%93514.%2010.1080/03007995.2024.2383731." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 10.1136/bmj.n71.
</cite> [<a href="https://doi.org/10.1136/bmj.n71" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8005924/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33782057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Page%20MJ,%20McKenzie%20JE,%20Bossuyt%20PM,%20et%20al.%20The%20PRISMA%202020%20statement:%20an%20updated%20guideline%20for%20reporting%20systematic%20reviews.%20BMJ.%202021;372:n71.%2010.1136/bmj.n71." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions: cochrane. 2024. Available from: <a href="http://www.training.cochrane.org/handbook" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.training.cochrane.org/handbook</a>.</cite>
</li>
<li id="CR19">
<span class="label">19.</span><cite>Guideline for good clinical practice E6(R2): Committee for Human Medicinal Products European Medicines Agency. 2016. Available from: <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf</a>.</cite>
</li>
<li id="CR20">
<span class="label">20.</span><cite>Keus F, Wetterslev J, Gluud C, van Laarhoven CJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol. 2010;10:90. 10.1186/1471-2288-10-90.
</cite> [<a href="https://doi.org/10.1186/1471-2288-10-90" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2959031/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20920306/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Keus%20F,%20Wetterslev%20J,%20Gluud%20C,%20van%20Laarhoven%20CJ.%20Evidence%20at%20a%20glance:%20error%20matrix%20approach%20for%20overviewing%20available%20evidence.%20BMC%20Med%20Res%20Methodol.%202010;10:90.%2010.1186/1471-2288-10-90." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14:120. 10.1186/1471-2288-14-120.
</cite> [<a href="https://doi.org/10.1186/1471-2288-14-120" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4251848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25416419/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jakobsen%20JC,%20Wetterslev%20J,%20Winkel%20P,%20Lange%20T,%20Gluud%20C.%20Thresholds%20for%20statistical%20and%20clinical%20significance%20in%20systematic%20reviews%20with%20meta-analytic%20methods.%20BMC%20Med%20Res%20Methodol.%202014;14:120.%2010.1186/1471-2288-14-120." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. 10.1016/0197-2456(86)90046-2.
</cite> [<a href="https://doi.org/10.1016/0197-2456(86)90046-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3802833/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?DerSimonian%20R,%20Laird%20N.%20Meta-analysis%20in%20clinical%20trials.%20Control%20Clin%20Trials.%201986;7:177%E2%80%9388.%2010.1016/0197-2456(86)90046-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987;6:341–50. 10.1002/sim.4780060325.
</cite> [<a href="https://doi.org/10.1002/sim.4780060325" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3616287/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?DeMets%20DL.%20Methods%20for%20combining%20randomized%20clinical%20trials:%20strengths%20and%20limitations.%20Stat%20Med.%201987;6:341%E2%80%9350.%2010.1002/sim.4780060325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Hardin JW, Hilbe JM. Estimation and testing of binomial and beta-binomial regression models with and without zero inflation. Stand Genomic Sci. 2014;14:292–303. 10.1177/1536867x1401400204.</cite> [<a href="https://scholar.google.com/scholar_lookup?Hardin%20JW,%20Hilbe%20JM.%20Estimation%20and%20testing%20of%20binomial%20and%20beta-binomial%20regression%20models%20with%20and%20without%20zero%20inflation.%20Stand%20Genomic%20Sci.%202014;14:292%E2%80%93303.%2010.1177/1536867x1401400204." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>StataCorp. Stata statistical software: Release 18 College Station, TX: StataCorp LLC. 2023. Available from: <a href="http://www.stata.com" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.stata.com</a>.</cite>
</li>
<li id="CR26">
<span class="label">26.</span><cite>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA) [pdf] 2017. [1–119 pp.]: Copenhagen: Copenhagen Trial Unit. Available from: <a href="http://ctu.dk/wp-content/uploads/2021/03/2017-10-10-TSA-Manual-ENG_ER.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://ctu.dk/wp-content/uploads/2021/03/2017-10-10-TSA-Manual-ENG_ER.pdf</a>.</cite>
</li>
<li id="CR27">
<span class="label">27.</span><cite>TSA - trial sequential analysis. Copenhagen Trial Unit. Available from: <a href="http://www.ctu.dk/tsa/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.ctu.dk/tsa/</a>.</cite>
</li>
<li id="CR28">
<span class="label">28.</span><cite>Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–2. 10.1016/j.jclinepi.2010.09.011.
</cite> [<a href="https://doi.org/10.1016/j.jclinepi.2010.09.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21185693/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guyatt%20GH,%20Oxman%20AD,%20Sch%C3%BCnemann%20HJ,%20Tugwell%20P,%20Knottnerus%20A.%20GRADE%20guidelines:%20a%20new%20series%20of%20articles%20in%20the%20Journal%20of%20Clinical%20Epidemiology.%20J%20Clin%20Epidemiol.%202011;64:380%E2%80%932.%2010.1016/j.jclinepi.2010.09.011." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. 10.1136/bmj.39489.470347.AD.
</cite> [<a href="https://doi.org/10.1136/bmj.39489.470347.AD" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2335261/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18436948/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guyatt%20GH,%20Oxman%20AD,%20Vist%20GE,%20et%20al.%20GRADE:%20an%20emerging%20consensus%20on%20rating%20quality%20of%20evidence%20and%20strength%20of%20recommendations.%20BMJ.%202008;336:924%E2%80%936.%2010.1136/bmj.39489.470347.AD." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Schünemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169:677–80.
</cite> [<a href="/articles/PMC202287/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14517128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sch%C3%BCnemann%20HJ,%20Best%20D,%20Vist%20G,%20Oxman%20AD.%20Letters,%20numbers,%20symbols%20and%20words:%20how%20to%20communicate%20grades%20of%20evidence%20and%20recommendations.%20CMAJ.%202003;169:677%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. 10.1136/bmj.315.7109.629.
</cite> [<a href="https://doi.org/10.1136/bmj.315.7109.629" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2127453/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9310563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Egger%20M,%20Smith%20GD,%20Schneider%20M,%20Minder%20C.%20Bias%20in%20meta-analysis%20detected%20by%20a%20simple,%20graphical%20test.%20BMJ.%201997;315:629%E2%80%9334.%2010.1136/bmj.315.7109.629." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101. 10.2307/2533446.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/7786990/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Begg%20CB,%20Mazumdar%20M.%20Operating%20characteristics%20of%20a%20rank%20correlation%20test%20for%20publication%20bias.%20Biometrics.%201994;50:1088%E2%80%93101.%2010.2307/2533446." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42:1724–32. 10.2337/dc19-0749.
</cite> [<a href="https://doi.org/10.2337/dc19-0749" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31186300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Aroda%20VR,%20Rosenstock%20J,%20Terauchi%20Y,%20et%20al.%20PIONEER%201:%20randomized%20clinical%20trial%20of%20the%20efficacy%20and%20safety%20of%20oral%20semaglutide%20monotherapy%20in%20comparison%20with%20placebo%20in%20patients%20with%20type%202%20diabetes.%20Diabetes%20Care.%202019;42:1724%E2%80%9332.%2010.2337/dc19-0749." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67:470–82. 10.1007/s00125-023-06053-9.
</cite> [<a href="https://doi.org/10.1007/s00125-023-06053-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10844353/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38095657/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bl%C3%BCher%20M,%20Rosenstock%20J,%20Hoefler%20J,%20Manuel%20R,%20Hennige%20AM.%20Dose-response%20effects%20on%20HbA(1c)%20and%20bodyweight%20reduction%20of%20survodutide,%20a%20dual%20glucagon/GLP-1%20receptor%20agonist,%20compared%20with%20placebo%20and%20open-label%20semaglutide%20in%20people%20with%20type%202%20diabetes:%20a%20randomised%20clinical%20trial.%20Diabetologia.%202024;67:470%E2%80%9382.%2010.1007/s00125-023-06053-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318:1460–70. 10.1001/jama.2017.14752.
</cite> [<a href="https://doi.org/10.1001/jama.2017.14752" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5817971/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29049653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Davies%20M,%20Pieber%20TR,%20Hartoft-Nielsen%20ML,%20Hansen%20OKH,%20Jabbour%20S,%20Rosenstock%20J.%20Effect%20of%20oral%20semaglutide%20compared%20with%20placebo%20and%20subcutaneous%20semaglutide%20on%20glycemic%20control%20in%20patients%20with%20type%202%20diabetes:%20a%20randomized%20clinical%20trial.%20JAMA.%202017;318:1460%E2%80%9370.%2010.1001/jama.2017.14752." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971–84. 10.1016/s0140-6736(21)00213-0.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)00213-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33667417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Davies%20M,%20F%C3%A6rch%20L,%20Jeppesen%20OK,%20et%20al.%20Semaglutide%202%C2%B74%20mg%20once%20a%20week%20in%20adults%20with%20overweight%20or%20obesity,%20and%20type%202%20diabetes%20(STEP%202):%20a%20randomised,%20double-blind,%20double-dummy,%20placebo-controlled,%20phase%203%20trial.%20Lancet.%202021;397:971%E2%80%9384.%2010.1016/s0140-6736(21)00213-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54:1150–61. 10.1111/apt.16608.
</cite> [<a href="https://doi.org/10.1111/apt.16608" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9292692/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34570916/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Flint%20A,%20Andersen%20G,%20Hockings%20P,%20et%20al.%20Randomised%20clinical%20trial:%20semaglutide%20versus%20placebo%20reduced%20liver%20steatosis%20but%20not%20liver%20stiffness%20in%20subjects%20with%20non-alcoholic%20fatty%20liver%20disease%20assessed%20by%20magnetic%20resonance%20imaging.%20Aliment%20Pharmacol%20Ther.%202021;54:1150%E2%80%9361.%2010.1111/apt.16608." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23:754–62. 10.1111/dom.14280.
</cite> [<a href="https://doi.org/10.1111/dom.14280" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7898914/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33269530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Friedrichsen%20M,%20Breitschaft%20A,%20Tadayon%20S,%20Wizert%20A,%20Skovgaard%20D.%20The%20effect%20of%20semaglutide%202.4%20mg%20once%20weekly%20on%20energy%20intake,%20appetite,%20control%20of%20eating,%20and%20gastric%20emptying%20in%20adults%20with%20obesity.%20Diabetes%20Obes%20Metab.%202021;23:754%E2%80%9362.%2010.1111/dom.14280." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083–91. 10.1038/s41591-022-02026-4.
</cite> [<a href="https://doi.org/10.1038/s41591-022-02026-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9556320/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36216945/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Garvey%20WT,%20Batterham%20RL,%20Bhatta%20M,%20et%20al.%20Two-year%20effects%20of%20semaglutide%20in%20adults%20with%20overweight%20or%20obesity:%20the%20STEP%205%20trial.%20Nat%20Med.%202022;28:2083%E2%80%9391.%2010.1038/s41591-022-02026-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2019;58:781–91. 10.1007/s40262-018-0728-4.
</cite> [<a href="https://doi.org/10.1007/s40262-018-0728-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30565096/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Granhall%20C,%20Donsmark%20M,%20Blicher%20TM,%20et%20al.%20Safety%20and%20pharmacokinetics%20of%20single%20and%20multiple%20ascending%20doses%20of%20the%20novel%20oral%20human%20GLP-1%20analogue,%20oral%20semaglutide,%20in%20healthy%20subjects%20and%20subjects%20with%20type%202%20diabetes.%20Clin%20Pharmacokinet.%202019;58:781%E2%80%9391.%2010.1007/s40262-018-0728-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10:418–29. 10.1016/s2213-8587(22)00085-7.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(22)00085-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35468322/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Heise%20T,%20Mari%20A,%20DeVries%20JH,%20et%20al.%20Effects%20of%20subcutaneous%20tirzepatide%20versus%20placebo%20or%20semaglutide%20on%20pancreatic%20islet%20function%20and%20insulin%20sensitivity%20in%20adults%20with%20type%202%20diabetes:%20a%20multicentre,%20randomised,%20double-blind,%20parallel-arm,%20phase%201%20clinical%20trial.%20Lancet%20Diabetes%20Endocrinol.%202022;10:418%E2%80%9329.%2010.1016/s2213-8587(22)00085-7." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51. 10.1056/NEJMoa1901118.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1901118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31185157/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Husain%20M,%20Birkenfeld%20AL,%20Donsmark%20M,%20et%20al.%20Oral%20semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes.%20N%20Engl%20J%20Med.%202019;381:841%E2%80%9351.%2010.1056/NEJMoa1901118." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10:193–206. 10.1016/s2213-8587(22)00008-0.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(22)00008-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35131037/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kadowaki%20T,%20Isendahl%20J,%20Khalid%20U,%20et%20al.%20Semaglutide%20once%20a%20week%20in%20adults%20with%20overweight%20or%20obesity,%20with%20or%20without%20type%202%20diabetes%20in%20an%20east%20Asian%20population%20(STEP%206):%20a%20randomised,%20double-blind,%20double-dummy,%20placebo-controlled,%20phase%203a%20trial.%20Lancet%20Diabetes%20Endocrinol.%202022;10:193%E2%80%93206.%2010.1016/s2213-8587(22)00008-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017;60:1390–9. 10.1007/s00125-017-4289-0.
</cite> [<a href="https://doi.org/10.1007/s00125-017-4289-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5491562/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28526920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kapitza%20C,%20Dahl%20K,%20Jacobsen%20JB,%20Axelsen%20MB,%20Flint%20A.%20Effects%20of%20semaglutide%20on%20beta%20cell%20function%20and%20glycaemic%20control%20in%20participants%20with%20type%202%20diabetes:%20a%20randomised,%20double-blind,%20placebo-controlled%20trial.%20Diabetologia.%202017;60:1390%E2%80%939.%2010.1007/s00125-017-4289-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705–19. 10.1016/s0140-6736(23)01185-6.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(23)01185-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37385278/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Knop%20FK,%20Aroda%20VR,%20do%20Vale%20RD,%20et%20al.%20Oral%20semaglutide%2050%20mg%20taken%20once%20per%20day%20in%20adults%20with%20overweight%20or%20obesity%20(OASIS%201):%20a%20randomised,%20double-blind,%20placebo-controlled,%20phase%203%20trial.%20Lancet.%202023;402:705%E2%80%9319.%2010.1016/s0140-6736(23)01185-6." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–84. 10.1056/NEJMoa2306963.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2306963" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37622681/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kosiborod%20MN,%20Abildstr%C3%B8m%20SZ,%20Borlaug%20BA,%20et%20al.%20Semaglutide%20in%20patients%20with%20heart%20failure%20with%20preserved%20ejection%20fraction%20and%20obesity.%20N%20Engl%20J%20Med.%202023;389:1069%E2%80%9384.%2010.1056/NEJMoa2306963." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390:1394–407. 10.1056/NEJMoa2313917.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2313917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38587233/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kosiborod%20MN,%20Petrie%20MC,%20Borlaug%20BA,%20et%20al.%20Semaglutide%20in%20patients%20with%20obesity-related%20heart%20failure%20and%20type%202%20diabetes.%20N%20Engl%20J%20Med.%202024;390:1394%E2%80%93407.%2010.1056/NEJMoa2313917." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. 10.1056/NEJMoa2307563.</cite> [<a href="https://doi.org/10.1056/NEJMoa2307563" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37952131/" class="usa-link">PubMed</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Lingvay I, Desouza CV, Lalic KS, et al. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care. 2018;41:1926–37. 10.2337/dc17-2381.
</cite> [<a href="https://doi.org/10.2337/dc17-2381" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30026333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lingvay%20I,%20Desouza%20CV,%20Lalic%20KS,%20et%20al.%20A%2026-week%20randomized%20controlled%20trial%20of%20semaglutide%20once%20daily%20versus%20liraglutide%20and%20placebo%20in%20patients%20with%20type%202%20diabetes%20suboptimally%20controlled%20on%20diet%20and%20exercise%20with%20or%20without%20metformin.%20Diabetes%20Care.%202018;41:1926%E2%80%9337.%2010.2337/dc17-2381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511–22. 10.1016/s2468-1253(23)00068-7.
</cite> [<a href="https://doi.org/10.1016/S2468-1253(23)00068-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10792518/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36934740/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Loomba%20R,%20Abdelmalek%20MF,%20Armstrong%20MJ,%20et%20al.%20Semaglutide%202.4%20mg%20once%20weekly%20in%20patients%20with%20non-alcoholic%20steatohepatitis-related%20cirrhosis:%20a%20randomised,%20placebo-controlled%20phase%202%20trial.%20Lancet%20Gastroenterol%20Hepatol.%202023;8:511%E2%80%9322.%2010.1016/s2468-1253(23)00068-7." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44. 10.1056/NEJMoa1607141.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1607141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27633186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marso%20SP,%20Bain%20SC,%20Consoli%20A,%20et%20al.%20Semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes.%20N%20Engl%20J%20Med.%202016;375:1834%E2%80%9344.%2010.1056/NEJMoa1607141." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515–27. 10.1016/s2213-8587(19)30192-5.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(19)30192-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31189517/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mosenzon%20O,%20Blicher%20TM,%20Rosenlund%20S,%20et%20al.%20Efficacy%20and%20safety%20of%20oral%20semaglutide%20in%20patients%20with%20type%202%20diabetes%20and%20moderate%20renal%20impairment%20(PIONEER%205):%20a%20placebo-controlled,%20randomised,%20phase%203a%20trial.%20Lancet%20Diabetes%20Endocrinol.%202019;7:515%E2%80%9327.%2010.1016/s2213-8587(19)30192-5." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Mu Y, Bao X, Eliaschewitz FG, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024;12:184–95. 10.1016/s2213-8587(23)00388-1.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(23)00388-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38330988/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mu%20Y,%20Bao%20X,%20Eliaschewitz%20FG,%20et%20al.%20Efficacy%20and%20safety%20of%20once%20weekly%20semaglutide%202.4%20mg%20for%20weight%20management%20in%20a%20predominantly%20east%20Asian%20population%20with%20overweight%20or%20obesity%20(STEP%207):%20a%20double-blind,%20multicentre,%20randomised%20controlled%20trial.%20Lancet%20Diabetes%20Endocrinol.%202024;12:184%E2%80%9395.%2010.1016/s2213-8587(23)00388-1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231–41. 10.2337/dc15-0165.
</cite> [<a href="https://doi.org/10.2337/dc15-0165" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26358288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nauck%20MA,%20Petrie%20JR,%20Sesti%20G,%20et%20al.%20A%20phase%202,%20randomized,%20dose-finding%20study%20of%20the%20novel%20once-weekly%20human%20GLP-1%20analog,%20semaglutide,%20compared%20with%20placebo%20and%20open-label%20liraglutide%20in%20patients%20with%20type%202%20diabetes.%20Diabetes%20Care.%202016;39:231%E2%80%9341.%2010.2337/dc15-0165." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113–24. 10.1056/NEJMoa2028395.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2028395" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33185364/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Newsome%20PN,%20Buchholtz%20K,%20Cusi%20K,%20et%20al.%20A%20placebo-controlled%20trial%20of%20subcutaneous%20semaglutide%20in%20nonalcoholic%20steatohepatitis.%20N%20Engl%20J%20Med.%202021;384:1113%E2%80%9324.%2010.1056/NEJMoa2028395." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637–49. 10.1016/s0140-6736(18)31773-2.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(18)31773-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30122305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?O%E2%80%99Neil%20PM,%20Birkenfeld%20AL,%20McGowan%20B,%20et%20al.%20Efficacy%20and%20safety%20of%20semaglutide%20compared%20with%20liraglutide%20and%20placebo%20for%20weight%20loss%20in%20patients%20with%20obesity:%20a%20randomised,%20double-blind,%20placebo%20and%20active%20controlled,%20dose-ranging,%20phase%202%20trial.%20Lancet.%202018;392:637%E2%80%9349.%2010.1016/s0140-6736(18)31773-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024. 10.1056/NEJMoa2403347.</cite> [<a href="https://doi.org/10.1056/NEJMoa2403347" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38785209/" class="usa-link">PubMed</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394:39–50. 10.1016/s0140-6736(19)31271-1.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(19)31271-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31186120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pratley%20R,%20Amod%20A,%20Hoff%20ST,%20et%20al.%20Oral%20semaglutide%20versus%20subcutaneous%20liraglutide%20and%20placebo%20in%20type%202%20diabetes%20(PIONEER%204):%20a%20randomised,%20double-blind,%20phase%203a%20trial.%20Lancet.%202019;394:39%E2%80%9350.%2010.1016/s0140-6736(19)31271-1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103:2291–301. 10.1210/jc.2018-00070.
</cite> [<a href="https://doi.org/10.1210/jc.2018-00070" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5991220/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29688502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rodbard%20HW,%20Lingvay%20I,%20Reed%20J,%20et%20al.%20Semaglutide%20added%20to%20basal%20insulin%20in%20type%202%20diabetes%20(SUSTAIN%205):%20a%20randomized,%20controlled%20trial.%20J%20Clin%20Endocrinol%20Metab.%202018;103:2291%E2%80%93301.%2010.1210/jc.2018-00070." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138–50. 10.1001/jama.2021.23619.
</cite> [<a href="https://doi.org/10.1001/jama.2021.23619" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8753508/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35015037/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rubino%20DM,%20Greenway%20FL,%20Khalid%20U,%20et%20al.%20Effect%20of%20weekly%20subcutaneous%20semaglutide%20vs%20daily%20liraglutide%20on%20body%20weight%20in%20adults%20with%20overweight%20or%20obesity%20without%20diabetes:%20the%20STEP%208%20randomized%20clinical%20trial.%20JAMA.%202022;327:138%E2%80%9350.%2010.1001/jama.2021.23619." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251–60. 10.1016/s2213-8587(17)30013-x.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(17)30013-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28110911/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sorli%20C,%20Harashima%20SI,%20Tsoukas%20GM,%20et%20al.%20Efficacy%20and%20safety%20of%20once-weekly%20semaglutide%20monotherapy%20versus%20placebo%20in%20patients%20with%20type%202%20diabetes%20(SUSTAIN%201):%20a%20double-blind,%20randomised,%20placebo-controlled,%20parallel-group,%20multinational,%20multicentre%20phase%203a%20trial.%20Lancet%20Diabetes%20Endocrinol.%202017;5:251%E2%80%9360.%2010.1016/s2213-8587(17)30013-x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403–13. 10.1001/jama.2021.1831.
</cite> [<a href="https://doi.org/10.1001/jama.2021.1831" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7905697/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33625476/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wadden%20TA,%20Bailey%20TS,%20Billings%20LK,%20et%20al.%20Effect%20of%20subcutaneous%20semaglutide%20vs%20placebo%20as%20an%20adjunct%20to%20intensive%20behavioral%20therapy%20on%20body%20weight%20in%20adults%20with%20overweight%20or%20obesity:%20the%20STEP%203%20randomized%20clinical%20trial.%20JAMA.%202021;325:1403%E2%80%9313.%2010.1001/jama.2021.1831." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387:2245–57. 10.1056/NEJMoa2208601.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2208601" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9997064/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36322838/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Weghuber%20D,%20Barrett%20T,%20Barrientos-P%C3%A9rez%20M,%20et%20al.%20Once-weekly%20semaglutide%20in%20adolescents%20with%20obesity.%20N%20Engl%20J%20Med.%202022;387:2245%E2%80%9357.%2010.1056/NEJMoa2208601." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. 10.1056/NEJMoa2032183.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2032183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33567185/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wilding%20JPH,%20Batterham%20RL,%20Calanna%20S,%20et%20al.%20Once-weekly%20semaglutide%20in%20adults%20with%20overweight%20or%20obesity.%20N%20Engl%20J%20Med.%202021;384:989%E2%80%931002.%2010.1056/NEJMoa2032183." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8:377–91. 10.1016/s2213-8587(20)30075-9.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(20)30075-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32333875/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yamada%20Y,%20Katagiri%20H,%20Hamamoto%20Y,%20et%20al.%20Dose-response,%20efficacy,%20and%20safety%20of%20oral%20semaglutide%20monotherapy%20in%20Japanese%20patients%20with%20type%202%20diabetes%20(PIONEER%209):%20a%2052-week,%20phase%202/3a,%20randomised,%20controlled%20trial.%20Lancet%20Diabetes%20Endocrinol.%202020;8:377%E2%80%9391.%2010.1016/s2213-8587(20)30075-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:356–67. 10.1016/s2213-8587(19)30066-x.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(19)30066-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30833170/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zinman%20B,%20Bhosekar%20V,%20Busch%20R,%20et%20al.%20Semaglutide%20once%20weekly%20as%20add-on%20to%20SGLT-2%20inhibitor%20therapy%20in%20type%202%20diabetes%20(SUSTAIN%209):%20a%20randomised,%20placebo-controlled%20trial.%20Lancet%20Diabetes%20Endocrinol.%202019;7:356%E2%80%9367.%2010.1016/s2213-8587(19)30066-x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42:2262–71. 10.2337/dc19-0898.
</cite> [<a href="https://doi.org/10.2337/dc19-0898" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7364672/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31530667/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zinman%20B,%20Aroda%20VR,%20Buse%20JB,%20et%20al.%20Efficacy,%20safety,%20and%20tolerability%20of%20oral%20semaglutide%20versus%20placebo%20added%20to%20insulin%20with%20or%20without%20metformin%20in%20patients%20with%20type%202%20diabetes:%20the%20PIONEER%208%20trial.%20Diabetes%20Care.%202019;42:2262%E2%80%9371.%2010.2337/dc19-0898." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Wang W, Bain SC, Bian F, et al. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, phase IIIa, randomised trial. Diabetologia. 2024;67:1783–99. 10.1007/s00125-024-06142-3.
</cite> [<a href="https://doi.org/10.1007/s00125-024-06142-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11410837/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38985162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20W,%20Bain%20SC,%20Bian%20F,%20et%20al.%20Efficacy%20and%20safety%20of%20oral%20semaglutide%20monotherapy%20vs%20placebo%20in%20a%20predominantly%20Chinese%20population%20with%20type%202%20diabetes%20(PIONEER%2011):%20a%20double-blind,%20phase%20IIIa,%20randomised%20trial.%20Diabetologia.%202024;67:1783%E2%80%9399.%2010.1007/s00125-024-06142-3." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Effect of subcutaneous semaglutide on kidney transplant candidacy (RAISE-KT). 2021. Available from: <a href="https://clinicaltrials.gov/study/NCT04741074" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT04741074</a>.</cite>
</li>
<li id="CR70">
<span class="label">70.</span><cite>Investigation of the safety and efficacy of semaglutide s.c. in combination with NNC0480–0389 in participants with type 2 diabetes – a dose finding study. EU Clinical Trials Register. 2020. Available from: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004863-14/results" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004863-14/results</a>.</cite>
</li>
<li id="CR71">
<span class="label">71.</span><cite>Selvarajah V, Robertson D, Hansen L, et al. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 2024;106:1170–80. 10.1016/j.kint.2024.08.023.
</cite> [<a href="https://doi.org/10.1016/j.kint.2024.08.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39218393/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Selvarajah%20V,%20Robertson%20D,%20Hansen%20L,%20et%20al.%20A%20randomized%20phase%202b%20trial%20examined%20the%20effects%20of%20the%20glucagon-like%20peptide-1%20and%20glucagon%20receptor%20agonist%20cotadutide%20on%20kidney%20outcomes%20in%20patients%20with%20diabetic%20kidney%20disease.%20Kidney%20Int.%202024;106:1170%E2%80%9380.%2010.1016/j.kint.2024.08.023." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<span class="label">72.</span><cite>McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12:631–42. 10.1016/S2213-8587(24)00182-7.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(24)00182-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39089293/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McGowan%20BM,%20Bruun%20JM,%20Capehorn%20M,%20et%20al.%20Efficacy%20and%20safety%20of%20once-weekly%20semaglutide%202.4%20mg%20versus%20placebo%20in%20people%20with%20obesity%20and%20prediabetes%20(STEP%2010):%20a%20randomised,%20double-blind,%20placebo-controlled,%20multicentre%20phase%203%20trial.%20Lancet%20Diabetes%20Endocrinol.%202024;12:631%E2%80%9342.%2010.1016/S2213-8587(24)00182-7." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR73">
<span class="label">73.</span><cite>Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391:1573–83. 10.1056/NEJMoa2403664.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2403664" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39476339/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bliddal%20H,%20Bays%20H,%20Czernichow%20S,%20et%20al.%20Once-weekly%20semaglutide%20in%20persons%20with%20obesity%20and%20knee%20osteoarthritis.%20N%20Engl%20J%20Med.%202024;391:1573%E2%80%9383.%2010.1056/NEJMoa2403664." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR74">
<span class="label">74.</span><cite>Sivalingam S, Wasehuus VS, Rotbain Curovic V, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: a randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26:54–64. 10.1111/dom.15287.
</cite> [<a href="https://doi.org/10.1111/dom.15287" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37722966/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sivalingam%20S,%20Wasehuus%20VS,%20Rotbain%20Curovic%20V,%20et%20al.%20Albuminuria-lowering%20effect%20of%20adding%20semaglutide%20on%20top%20of%20empagliflozin%20in%20individuals%20with%20type%202%20diabetes:%20a%20randomized%20and%20placebo-controlled%20study.%20Diabetes%20Obes%20Metab.%202024;26:54%E2%80%9364.%2010.1111/dom.15287." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR75">
<span class="label">75.</span><cite>Apperloo EM, Gorriz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2024. 10.1038/s41591-024-03327-6.</cite> [<a href="https://doi.org/10.1038/s41591-024-03327-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39455729/" class="usa-link">PubMed</a>]</li>
<li id="CR76">
<span class="label">76.</span><cite>Gabe MBN, Breitschaft A, Knop FK, et al. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: a randomized controlled trial. Diabetes Obes Metab. 2024;26:4480–9. 10.1111/dom.15802.
</cite> [<a href="https://doi.org/10.1111/dom.15802" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39082206/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gabe%20MBN,%20Breitschaft%20A,%20Knop%20FK,%20et%20al.%20Effect%20of%20oral%20semaglutide%20on%20energy%20intake,%20appetite,%20control%20of%20eating%20and%20gastric%20emptying%20in%20adults%20living%20with%20obesity:%20a%20randomized%20controlled%20trial.%20Diabetes%20Obes%20Metab.%202024;26:4480%E2%80%939.%2010.1111/dom.15802." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR77">
<span class="label">77.</span><cite>A research study to look into how well semaglutide medicine works at different doses in people with type 2 diabetes and overweight. 2024. Available from: <a href="https://clinicaltrials.gov/study/NCT05486065" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT05486065</a>.</cite>
</li>
<li id="CR78">
<span class="label">78.</span><cite>Amin NB, Frederich R, Tsamandouras N, et al. Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: a dose-ranging, phase 2, randomized, placebo-controlled study. Diabetes Obes Metab. 2025;27:215–27. 10.1111/dom.16005.
</cite> [<a href="https://doi.org/10.1111/dom.16005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11618248/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39415344/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Amin%20NB,%20Frederich%20R,%20Tsamandouras%20N,%20et%20al.%20Evaluation%20of%20an%20oral%20small-molecule%20glucagon-like%20peptide-1%20receptor%20agonist,%20lotiglipron,%20for%20type%202%20diabetes%20and%20obesity:%20a%20dose-ranging,%20phase%202,%20randomized,%20placebo-controlled%20study.%20Diabetes%20Obes%20Metab.%202025;27:215%E2%80%9327.%2010.1111/dom.16005." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR79">
<span class="label">79.</span><cite>Eckard AR, Wu Q, Sattar A, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes Endocrinol. 2024;12:523–34. 10.1016/S2213-8587(24)00150-5.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(24)00150-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11417641/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38964353/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Eckard%20AR,%20Wu%20Q,%20Sattar%20A,%20et%20al.%20Once-weekly%20semaglutide%20in%20people%20with%20HIV-associated%20lipohypertrophy:%20a%20randomised,%20double-blind,%20placebo-controlled%20phase%202b%20single-centre%20clinical%20trial.%20Lancet%20Diabetes%20Endocrinol.%202024;12:523%E2%80%9334.%2010.1016/S2213-8587(24)00150-5." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR80">
<span class="label">80.</span><cite>McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392:2001–12. 10.1056/NEJMoa2501006.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2501006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40162642/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McGuire%20DK,%20Marx%20N,%20Mulvagh%20SL,%20et%20al.%20Oral%20semaglutide%20and%20cardiovascular%20outcomes%20in%20high-risk%20type%202%20diabetes.%20N%20Engl%20J%20Med.%202025;392:2001%E2%80%9312.%2010.1056/NEJMoa2501006." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR81">
<span class="label">81.</span><cite>Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis. N Engl J Med. 2025;392:2089–99. 10.1056/NEJMoa2413258.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2413258" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40305708/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sanyal%20AJ,%20Newsome%20PN,%20Kliers%20I,%20et%20al.%20Phase%203%20trial%20of%20semaglutide%20in%20metabolic%20dysfunction%E2%80%93associated%20steatohepatitis.%20N%20Engl%20J%20Med.%202025;392:2089%E2%80%9399.%2010.1056/NEJMoa2413258." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR82">
<span class="label">82.</span><cite>Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405:1580–93. 10.1016/s0140-6736(25)00509-4.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(25)00509-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40169145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bonaca%20MP,%20Catarig%20AM,%20Houlind%20K,%20et%20al.%20Semaglutide%20and%20walking%20capacity%20in%20people%20with%20symptomatic%20peripheral%20artery%20disease%20and%20type%202%20diabetes%20(STRIDE):%20a%20phase%203b,%20double-blind,%20randomised,%20placebo-controlled%20trial.%20Lancet.%202025;405:1580%E2%80%9393.%2010.1016/s0140-6736(25)00509-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR83">
<span class="label">83.</span><cite>Korsatko S, Jensen L, Brunner M, et al. Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab. 2018;20:2565–73. 10.1111/dom.13422.
</cite> [<a href="https://doi.org/10.1111/dom.13422" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6221089/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29893488/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Korsatko%20S,%20Jensen%20L,%20Brunner%20M,%20et%20al.%20Effect%20of%20once-weekly%20semaglutide%20on%20the%20counterregulatory%20response%20to%20hypoglycaemia%20in%20people%20with%20type%202%20diabetes:%20a%20randomized,%20placebo-controlled,%20double-blind,%20crossover%20trial.%20Diabetes%20Obes%20Metab.%202018;20:2565%E2%80%9373.%2010.1111/dom.13422." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR84">
<span class="label">84.</span><cite>Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20:610–9. 10.1111/dom.13120.
</cite> [<a href="https://doi.org/10.1111/dom.13120" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5836914/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28941314/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hjerpsted%20JB,%20Flint%20A,%20Brooks%20A,%20Axelsen%20MB,%20Kvist%20T,%20Blundell%20J.%20Semaglutide%20improves%20postprandial%20glucose%20and%20lipid%20metabolism,%20and%20delays%20first-hour%20gastric%20emptying%20in%20subjects%20with%20obesity.%20Diabetes%20Obes%20Metab.%202018;20:610%E2%80%939.%2010.1111/dom.13120." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR85">
<span class="label">85.</span><cite>Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Bækdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23:581–8. 10.1111/dom.14255.
</cite> [<a href="https://doi.org/10.1111/dom.14255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7839771/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33184979/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gibbons%20C,%20Blundell%20J,%20Tetens%20Hoff%20S,%20Dahl%20K,%20Bauer%20R,%20B%C3%A6kdal%20T.%20Effects%20of%20oral%20semaglutide%20on%20energy%20intake,%20food%20preference,%20appetite,%20control%20of%20eating%20and%20body%20weight%20in%20subjects%20with%20type%202%20diabetes.%20Diabetes%20Obes%20Metab.%202021;23:581%E2%80%938.%2010.1111/dom.14255." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR86">
<span class="label">86.</span><cite>Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242–51. 10.1111/dom.12932.
</cite> [<a href="https://doi.org/10.1111/dom.12932" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5573908/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28266779/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Blundell%20J,%20Finlayson%20G,%20Axelsen%20M,%20et%20al.%20Effects%20of%20once-weekly%20semaglutide%20on%20appetite,%20energy%20intake,%20control%20of%20eating,%20food%20preference%20and%20body%20weight%20in%20subjects%20with%20obesity.%20Diabetes%20Obes%20Metab.%202017;19:1242%E2%80%9351.%2010.1111/dom.12932." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR87">
<span class="label">87.</span><cite>Pasqua MR, Tsoukas MA, Kobayati A, Aboznadah W, Jafar A, Haidar A. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat Med. 2025. 10.1038/s41591-024-03463-z.</cite> [<a href="https://doi.org/10.1038/s41591-024-03463-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12003151/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39794615/" class="usa-link">PubMed</a>]</li>
<li id="CR88">
<span class="label">88.</span><cite>Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414–25. 10.1001/jama.2021.3224.
</cite> [<a href="https://doi.org/10.1001/jama.2021.3224" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7988425/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33755728/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rubino%20D,%20Abrahamsson%20N,%20Davies%20M,%20et%20al.%20Effect%20of%20continued%20weekly%20subcutaneous%20semaglutide%20vs%20placebo%20on%20weight%20loss%20maintenance%20in%20adults%20with%20overweight%20or%20obesity:%20the%20STEP%204%20randomized%20clinical%20trial.%20JAMA.%202021;325:1414%E2%80%9325.%2010.1001/jama.2021.3224." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR89">
<span class="label">89.</span><cite>Shi A, Xie P, Nielsen LL, Skjøth TV, He X, Haugaard SP. Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy Chinese subjects: a double-blind, phase 1, randomized controlled trial. Adv Ther. 2021;38:550–61. 10.1007/s12325-020-01548-y.
</cite> [<a href="https://doi.org/10.1007/s12325-020-01548-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7854449/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33159658/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shi%20A,%20Xie%20P,%20Nielsen%20LL,%20Skj%C3%B8th%20TV,%20He%20X,%20Haugaard%20SP.%20Pharmacokinetics,%20safety%20and%20tolerability%20of%20once-weekly%20subcutaneous%20semaglutide%20in%20healthy%20Chinese%20subjects:%20a%20double-blind,%20phase%201,%20randomized%20controlled%20trial.%20Adv%20Ther.%202021;38:550%E2%80%9361.%2010.1007/s12325-020-01548-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR90">
<span class="label">90.</span><cite>Xie P, Abildlund MT, Bækdal TA, et al. A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects. Diabetes Obes Metab. 2024. 10.1111/dom.15624.</cite> [<a href="https://doi.org/10.1111/dom.15624" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38808476/" class="usa-link">PubMed</a>]</li>
<li id="CR91">
<span class="label">91.</span><cite>Ikushima I, Jensen L, Flint A, Nishida T, Zacho J, Irie S. A randomized trial investigating the pharmacokinetics, pharmacodynamics, and safety of subcutaneous semaglutide once-weekly in healthy male Japanese and Caucasian subjects. Adv Ther. 2018;35:531–44. 10.1007/s12325-018-0677-1.
</cite> [<a href="https://doi.org/10.1007/s12325-018-0677-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5910468/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29536338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ikushima%20I,%20Jensen%20L,%20Flint%20A,%20Nishida%20T,%20Zacho%20J,%20Irie%20S.%20A%20randomized%20trial%20investigating%20the%20pharmacokinetics,%20pharmacodynamics,%20and%20safety%20of%20subcutaneous%20semaglutide%20once-weekly%20in%20healthy%20male%20Japanese%20and%20Caucasian%20subjects.%20Adv%20Ther.%202018;35:531%E2%80%9344.%2010.1007/s12325-018-0677-1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR92">
<span class="label">92.</span><cite>Hansen MS, Wölfel EM, Jeromdesella S, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. eClin Med. 2024. 10.1016/j.eclinm.2024.102624.</cite> [<a href="https://doi.org/10.1016/j.eclinm.2024.102624" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11087719/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38737002/" class="usa-link">PubMed</a>]</li>
<li id="CR93">
<span class="label">93.</span><cite>Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatr. 2025. 10.1001/jamapsychiatry.2024.4789.</cite> [<a href="https://doi.org/10.1001/jamapsychiatry.2024.4789" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11822619/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39937469/" class="usa-link">PubMed</a>]</li>
<li id="CR94">
<span class="label">94.</span><cite>Vernstrøm L, Gullaksen S, Sørensen SS, Funck KL, Laugesen E, Poulsen PL. Separate and combined effects of empagliflozin and semaglutide on vascular function: a 32-week randomized trial. Diabetes Obes Metab. 2024;26:1624–35. 10.1111/dom.15464.
</cite> [<a href="https://doi.org/10.1111/dom.15464" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38240066/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vernstr%C3%B8m%20L,%20Gullaksen%20S,%20S%C3%B8rensen%20SS,%20Funck%20KL,%20Laugesen%20E,%20Poulsen%20PL.%20Separate%20and%20combined%20effects%20of%20empagliflozin%20and%20semaglutide%20on%20vascular%20function:%20a%2032-week%20randomized%20trial.%20Diabetes%20Obes%20Metab.%202024;26:1624%E2%80%9335.%2010.1111/dom.15464." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR95">
<span class="label">95.</span><cite>van Hout M, Forte P, Jensen TB, Boschini C, Bækdal TA. Effect of various dosing schedules on the pharmacokinetics of oral semaglutide: a randomised trial in healthy subjects. Clin Pharmacokinet. 2023;62:635–44. 10.1007/s40262-023-01223-9.
</cite> [<a href="https://doi.org/10.1007/s40262-023-01223-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10023024/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36932262/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?van%20Hout%20M,%20Forte%20P,%20Jensen%20TB,%20Boschini%20C,%20B%C3%A6kdal%20TA.%20Effect%20of%20various%20dosing%20schedules%20on%20the%20pharmacokinetics%20of%20oral%20semaglutide:%20a%20randomised%20trial%20in%20healthy%20subjects.%20Clin%20Pharmacokinet.%202023;62:635%E2%80%9344.%2010.1007/s40262-023-01223-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR96">
<span class="label">96.</span><cite>Ahren B, Comas L, Kumar H, et al. Abstracts of 52nd EASD annual meeting. Diabetologia. 2016;59:1–581. 10.1007/s00125-016-4046-9.
</cite> [<a href="https://doi.org/10.1007/s00125-016-4046-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7096097/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27539147/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ahren%20B,%20Comas%20L,%20Kumar%20H,%20et%20al.%20Abstracts%20of%2052nd%20EASD%20annual%20meeting.%20Diabetologia.%202016;59:1%E2%80%93581.%2010.1007/s00125-016-4046-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR97">
<span class="label">97.</span><cite>Marbury TC, Flint A, Jacobsen JB, Derving Karsbøl J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56:1381–90. 10.1007/s40262-017-0528-2.
</cite> [<a href="https://doi.org/10.1007/s40262-017-0528-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5648736/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28349386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marbury%20TC,%20Flint%20A,%20Jacobsen%20JB,%20Derving%20Karsb%C3%B8l%20J,%20Lasseter%20K.%20Pharmacokinetics%20and%20tolerability%20of%20a%20single%20dose%20of%20semaglutide,%20a%20human%20glucagon-like%20peptide-1%20analog,%20in%20subjects%20with%20and%20without%20renal%20impairment.%20Clin%20Pharmacokinet.%202017;56:1381%E2%80%9390.%2010.1007/s40262-017-0528-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR98">
<span class="label">98.</span><cite>Mather K, Mari A, Li J, et al. 58thEASD Annual Meeting of the European Association for the Study of Diabetes. Diabetologia. 2022;65:1–469. 10.1007/s00125-022-05755-w.
</cite> [<a href="https://doi.org/10.1007/s00125-022-05755-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9362525/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35920845/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mather%20K,%20Mari%20A,%20Li%20J,%20et%20al.%2058thEASD%20Annual%20Meeting%20of%20the%20European%20Association%20for%20the%20Study%20of%20Diabetes.%20Diabetologia.%202022;65:1%E2%80%93469.%2010.1007/s00125-022-05755-w." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR99">
<span class="label">99.</span><cite>Da BL, Satapathy SK. Semaglutide or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2021;385:e6. 10.1056/NEJMc2106921.
</cite> [<a href="https://doi.org/10.1056/NEJMc2106921" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34233104/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Da%20BL,%20Satapathy%20SK.%20Semaglutide%20or%20placebo%20for%20nonalcoholic%20steatohepatitis.%20N%20Engl%20J%20Med.%202021;385:e6.%2010.1056/NEJMc2106921." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR100">
<span class="label">100.</span><cite>Masaki T, Ozeki Y, Yoshida Y, et al. Glucagon-like peptide-1 receptor agonist semaglutide improves eating behavior and glycemic control in Japanese obese type 2 diabetic patients. Metabolites. 2022;12. 10.3390/metabo12020147.</cite> [<a href="https://doi.org/10.3390/metabo12020147" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8878247/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35208221/" class="usa-link">PubMed</a>]</li>
<li id="CR101">
<span class="label">101.</span><cite>Jensterle M, Vovk A, Kovac J, et al. 30th European congress on obesity (ECO 2023). Obes Facts. 2023;16:1–351. 10.1159/000530456.36209729
</cite> [<a href="https://scholar.google.com/scholar_lookup?Jensterle%20M,%20Vovk%20A,%20Kovac%20J,%20et%20al.%2030th%20European%20congress%20on%20obesity%20(ECO%202023).%20Obes%20Facts.%202023;16:1%E2%80%93351.%2010.1159/000530456.36209729" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR102">
<span class="label">102.</span><cite>Kapitza C, Lynge J, During M, Jensen C. Abstracts of the 48th EASD annual meeting of the European Association for the Study of Diabetes. Diabetologia. 2012;55:1–538. 10.1007/s00125-012-2688-9.22038521
</cite> [<a href="https://scholar.google.com/scholar_lookup?Kapitza%20C,%20Lynge%20J,%20During%20M,%20Jensen%20C.%20Abstracts%20of%20the%2048th%20EASD%20annual%20meeting%20of%20the%20European%20Association%20for%20the%20Study%20of%20Diabetes.%20Diabetologia.%202012;55:1%E2%80%93538.%2010.1007/s00125-012-2688-9.22038521" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR103">
<span class="label">103.</span><cite>Manubolu VS, Lakshmanan S, Kinninger A, et al. Effect of semaglutide on epicardial adipose tissue volume and density in type 2 diabetes: insights from the STOP randomized trial. J Am Coll Cardiol. 2024;83:1164. 10.1016/S0735-1097(24)03154-1.</cite> [<a href="https://doi.org/10.1016/j.jacc.2024.05.065" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39168573/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Manubolu%20VS,%20Lakshmanan%20S,%20Kinninger%20A,%20et%20al.%20Effect%20of%20semaglutide%20on%20epicardial%20adipose%20tissue%20volume%20and%20density%20in%20type%202%20diabetes:%20insights%20from%20the%20STOP%20randomized%20trial.%20J%20Am%20Coll%20Cardiol.%202024;83:1164.%2010.1016/S0735-1097(24)03154-1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR104">
<span class="label">104.</span><cite>Jensterle M, Ferjan S, Vovk A, Battelino T, Rizzo M, Janež A. Semaglutide reduces fat accumulation in the tongue: a randomized single-blind, pilot study. Diabetes Res Clin Pract. 2021;178:108935. 10.1016/j.diabres.2021.108935.
</cite> [<a href="https://doi.org/10.1016/j.diabres.2021.108935" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34217774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jensterle%20M,%20Ferjan%20S,%20Vovk%20A,%20Battelino%20T,%20Rizzo%20M,%20Jane%C5%BE%20A.%20Semaglutide%20reduces%20fat%20accumulation%20in%20the%20tongue:%20a%20randomized%20single-blind,%20pilot%20study.%20Diabetes%20Res%20Clin%20Pract.%202021;178:108935.%2010.1016/j.diabres.2021.108935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR105">
<span class="label">105.</span><cite>Verghese D, Manubolu VS, Alalawi L, et al. Association of Cardio-Ankle Vascular Index (CAVI) and duration of diabetes mellitus in the STOP (Semaglutide Treatment on Coronary Plaque Progression) randomized control trial. Am Heart J. 2021;242:170. 10.1016/j.ahj.2021.10.061.</cite> [<a href="https://scholar.google.com/scholar_lookup?Verghese%20D,%20Manubolu%20VS,%20Alalawi%20L,%20et%20al.%20Association%20of%20Cardio-Ankle%20Vascular%20Index%20(CAVI)%20and%20duration%20of%20diabetes%20mellitus%20in%20the%20STOP%20(Semaglutide%20Treatment%20on%20Coronary%20Plaque%20Progression)%20randomized%20control%20trial.%20Am%20Heart%20J.%202021;242:170.%2010.1016/j.ahj.2021.10.061." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR106">
<span class="label">106.</span><cite>Buse JB, Soule BP, Harty BJ, et al. 776-P: comparative effectiveness of SC semaglutide in adults with T2D in U.S. routine clinical practice—year 1 results of SEPRA, a randomized pragmatic clinical trial. Diabetes. 2023;72. 10.2337/db23-776-P.</cite>
</li>
<li id="CR107">
<span class="label">107.</span><cite>Lanthier L, Langlois MF, Plourde M, Cauchon M. For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points? Rev Med Interne. 2021;42:369–70. 10.1016/j.revmed.2021.03.334.
</cite> [<a href="https://doi.org/10.1016/j.revmed.2021.03.334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33838950/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lanthier%20L,%20Langlois%20MF,%20Plourde%20M,%20Cauchon%20M.%20For%20obese%20patients%20or%20for%20patients%20who%20are%20overweight%20and%20have%20an%20associated%20comorbidity,%20how%20safe%20and%20effective%20is%20semaglutide%20as%20compared%20with%20placebo%20as%20an%20adjunct%20to%20lifestyle%20intervention%20for%20reducing%20body%20weight%20and%20other%20related%20end%20points?%20Rev%20Med%20Interne.%202021;42:369%E2%80%9370.%2010.1016/j.revmed.2021.03.334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR108">
<span class="label">108.</span><cite>Navodnik MP, Janež A, Žuran I. The effect of additional treatment with empagliflozin or semaglutide on endothelial function and arterial stiffness in subjects with type 1 diabetes mellitus—ENDIS study. Pharmaceutics. 2023;15:1945.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics15071945" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10385568/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37514131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Navodnik%20MP,%20Jane%C5%BE%20A,%20%C5%BDuran%20I.%20The%20effect%20of%20additional%20treatment%20with%20empagliflozin%20or%20semaglutide%20on%20endothelial%20function%20and%20arterial%20stiffness%20in%20subjects%20with%20type%201%20diabetes%20mellitus%E2%80%94ENDIS%20study.%20Pharmaceutics.%202023;15:1945." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR109">
<span class="label">109.</span><cite>Andrews CN, Bharucha AE, Camilleri M, et al. Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans1. Neurogastroenterol Motil. 2007;19:716–23. 10.1111/j.1365-2982.2007.00923.x.
</cite> [<a href="https://doi.org/10.1111/j.1365-2982.2007.00923.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2538797/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17727392/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Andrews%20CN,%20Bharucha%20AE,%20Camilleri%20M,%20et%20al.%20Effects%20of%20glucagon-like%20peptide-1%20and%20sympathetic%20stimulation%20on%20gastric%20accommodation%20in%20humans1.%20Neurogastroenterol%20Motil.%202007;19:716%E2%80%9323.%2010.1111/j.1365-2982.2007.00923.x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR110">
<span class="label">110.</span><cite>Brudermanns B. Wirksamkeit und Sicherheit der oralen Semaglutid-Monotherapie. Diabetol Stoffwechsel. 2019;14:416–8. 10.1055/a-0979-7812.</cite> [<a href="https://scholar.google.com/scholar_lookup?Brudermanns%20B.%20Wirksamkeit%20und%20Sicherheit%20der%20oralen%20Semaglutid-Monotherapie.%20Diabetol%20Stoffwechsel.%202019;14:416%E2%80%938.%2010.1055/a-0979-7812." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR111">
<span class="label">111.</span><cite>Jensterle M, Ferjan S, Lezaic L, Socan A, Zaletel K, Janez PA. RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS. J Endocr Soc. 2022;6:A33. 10.1210/jendso/bvac150.070.</cite> [<a href="https://scholar.google.com/scholar_lookup?Jensterle%20M,%20Ferjan%20S,%20Lezaic%20L,%20Socan%20A,%20Zaletel%20K,%20Janez%20PA.%20RF24%20%7C%20PSUN116%20Once-weekly%20semaglutide%20delays%20a%20late%20phase%20gastric%20emptying%20of%20solid%20meal%20measured%20by%20repeated%20scintigraphic%20imaging%20in%20obese%20women%20with%20PCOS.%20J%20Endocr%20Soc.%202022;6:A33.%2010.1210/jendso/bvac150.070." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR112">
<span class="label">112.</span><cite>Campbell-Scherer D. Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes. Evid Based Med. 2017;22:57–8. 10.1136/ebmed-2016-110652.
</cite> [<a href="https://doi.org/10.1136/ebmed-2016-110652" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28270434/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Campbell-Scherer%20D.%20Semaglutide%20is%20non-inferior%20to%20placebo%20for%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes.%20Evid%20Based%20Med.%202017;22:57%E2%80%938.%2010.1136/ebmed-2016-110652." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR113">
<span class="label">113.</span><cite>Vernstrom L, Gullaksen S, Funck K, Laugesen E, Poulsen P. 58thEASD Annual Meeting of the European Association for the Study of Diabetes. Diabetologia. 2022;65:1–469. 10.1007/s00125-022-05755-w.
</cite> [<a href="https://doi.org/10.1007/s00125-022-05755-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9362525/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35920845/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vernstrom%20L,%20Gullaksen%20S,%20Funck%20K,%20Laugesen%20E,%20Poulsen%20P.%2058thEASD%20Annual%20Meeting%20of%20the%20European%20Association%20for%20the%20Study%20of%20Diabetes.%20Diabetologia.%202022;65:1%E2%80%93469.%2010.1007/s00125-022-05755-w." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR114">
<span class="label">114.</span><cite>Badulescu S, Di Vincenzo J, Gill H, Tabassum A, McKenzie A, Mansur R. 242. Adjunctive treatment with semaglutide for cognitive dysfunction in major depressive disorder: reduction in depression scores associated with increased HbA1c function and glucose levels. Biol Psychiatry. 2024;95:S198-S9. 10.1016/j.biopsych.2024.02.477.</cite>
</li>
<li id="CR115">
<span class="label">115.</span><cite>Jensterle M, Ferjan S, Ležaič L, et al. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. 2023;25:975–84. 10.1111/dom.14944.
</cite> [<a href="https://doi.org/10.1111/dom.14944" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36511825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jensterle%20M,%20Ferjan%20S,%20Le%C5%BEai%C4%8D%20L,%20et%20al.%20Semaglutide%20delays%204-hour%20gastric%20emptying%20in%20women%20with%20polycystic%20ovary%20syndrome%20and%20obesity.%20Diabetes%20Obes%20Metab.%202023;25:975%E2%80%9384.%2010.1111/dom.14944." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR116">
<span class="label">116.</span><cite>Dahal S, Ahmad K, Kinninger A, et al. Association of duration of diabetes and hemoglobin A1C with baseline coronary plaque burden in the STOP trial. J Cardiovasc Comput Tomogr. 2021;15:S7. 10.1016/j.jcct.2021.06.166.</cite> [<a href="https://scholar.google.com/scholar_lookup?Dahal%20S,%20Ahmad%20K,%20Kinninger%20A,%20et%20al.%20Association%20of%20duration%20of%20diabetes%20and%20hemoglobin%20A1C%20with%20baseline%20coronary%20plaque%20burden%20in%20the%20STOP%20trial.%20J%20Cardiovasc%20Comput%20Tomogr.%202021;15:S7.%2010.1016/j.jcct.2021.06.166." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR117">
<span class="label">117.</span><cite>Demmel V, Sandberg-Schaal A, Jacobsen JB, Golor G, Pettersson J, Flint A. No QTc prolongation with semaglutide: a thorough QT study in healthy subjects. Diabetes Ther. 2018;9:1441–56. 10.1007/s13300-018-0442-0.
</cite> [<a href="https://doi.org/10.1007/s13300-018-0442-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6064589/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29799100/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Demmel%20V,%20Sandberg-Schaal%20A,%20Jacobsen%20JB,%20Golor%20G,%20Pettersson%20J,%20Flint%20A.%20No%20QTc%20prolongation%20with%20semaglutide:%20a%20thorough%20QT%20study%20in%20healthy%20subjects.%20Diabetes%20Ther.%202018;9:1441%E2%80%9356.%2010.1007/s13300-018-0442-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR118">
<span class="label">118.</span><cite>Persson F, Sivalingam S, Wasehuus V, Curovic VR, Hansen T, Rossing P. Renal effects of empagliflozin alone or in combination with semaglutide in albuminuric type 2 diabetes: a randomized, placebo-controlled trial: TH-OR54. J Am Soc Nephrol. 2023;34:S125. </cite>
</li>
<li id="CR119">
<span class="label">119.</span><cite>Baekdal T, Blicher T, Donsmark M, Sondergaard F. Safety, tolerability, and pharmacokinetics of single escalating doses of oral semaglutide in healthy male subjects. Diabetes. 2017;66:A318.</cite> [<a href="https://scholar.google.com/scholar_lookup?Baekdal%20T,%20Blicher%20T,%20Donsmark%20M,%20Sondergaard%20F.%20Safety,%20tolerability,%20and%20pharmacokinetics%20of%20single%20escalating%20doses%20of%20oral%20semaglutide%20in%20healthy%20male%20subjects.%20Diabetes.%202017;66:A318." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR120">
<span class="label">120.</span><cite>Enebo L, Berthelsen K, Kankam M, et al. European Congress on Obesity (ECO Online 2021). 28th Congress, 10–13 May, 2021. ABSTRACTS. Obesity Facts. 2021;14:1–154. 10.1159/000515911.</cite>
</li>
<li id="CR121">
<span class="label">121.</span><cite>Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736–48. 10.1016/S0140-6736(21)00845-X.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)00845-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33894838/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Enebo%20LB,%20Berthelsen%20KK,%20Kankam%20M,%20et%20al.%20Safety,%20tolerability,%20pharmacokinetics,%20and%20pharmacodynamics%20of%20concomitant%20administration%20of%20multiple%20doses%20of%20cagrilintide%20with%20semaglutide%202.4%20mg%20for%20weight%20management:%20a%20randomised,%20controlled,%20phase%201b%20trial.%20Lancet.%202021;397:1736%E2%80%9348.%2010.1016/S0140-6736(21)00845-X." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR122">
<span class="label">122.</span><cite>Manubolu VS, Kinninger A, Aldana-Bitar J, et al. The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: results from STOP trial. Am Heart J. 2024;267:141. 10.1016/j.ahj.2023.08.057.</cite> [<a href="https://doi.org/10.1016/j.numecd.2025.104036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40287313/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Manubolu%20VS,%20Kinninger%20A,%20Aldana-Bitar%20J,%20et%20al.%20The%20impact%20of%20semaglutide%20on%20liver%20fat%20assessed%20by%20serial%20cardiac%20CT%20scans%20in%20patients%20with%20type%202%20diabetes:%20results%20from%20STOP%20trial.%20Am%20Heart%20J.%202024;267:141.%2010.1016/j.ahj.2023.08.057." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR123">
<span class="label">123.</span><cite>Sever MJ, Kovac J, Vovk A, Battelino S, Battelino T, Janez A. 6468 Once-weekly semaglutide and taste perception in women with obesity. J Endocr Soc. 2024;8. 10.1210/jendso/bvae163.013.</cite>
</li>
<li id="CR124">
<span class="label">124.</span><cite>Petković-Dabić J, Binić I, Carić B, et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules. 2025;15:46.
</cite> [<a href="https://doi.org/10.3390/biom15010046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11763288/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39858442/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Petkovi%C4%87-Dabi%C4%87%20J,%20Bini%C4%87%20I,%20Cari%C4%87%20B,%20et%20al.%20Effects%20of%20semaglutide%20treatment%20on%20psoriatic%20lesions%20in%20obese%20patients%20with%20type%202%20diabetes%20mellitus:%20an%20open-label,%20randomized%20clinical%20trial.%20Biomolecules.%202025;15:46." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR125">
<span class="label">125.</span><cite>Rodriguez P, Breslaw N, Xiao H, et al. De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: a single-centre, open-label randomised trial (TRANSITION-T2D). Diabetes Obes Metab. 2025;27:642–51. 10.1111/dom.16057.
</cite> [<a href="https://doi.org/10.1111/dom.16057" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11701190/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39532398/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rodriguez%20P,%20Breslaw%20N,%20Xiao%20H,%20et%20al.%20De-intensification%20of%20basal-bolus%20therapy%20by%20replacing%20prandial%20insulin%20with%20once-weekly%20subcutaneous%20semaglutide%20in%20individuals%20with%20well-controlled%20type%202%20diabetes:%20a%20single-centre,%20open-label%20randomised%20trial%20(TRANSITION-T2D).%20Diabetes%20Obes%20Metab.%202025;27:642%E2%80%9351.%2010.1111/dom.16057." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR126">
<span class="label">126.</span><cite>Gadve S, Chavanda K, Chavanda S, Hanamshetti S. Oral semaglutide in individuals with prediabetes to achieve and maintain normoglycaemia: an 18 months multicentre prospective randomised controlled study. Diabetologia. 2024;67(Suppl. 1):S542-S.</cite>
</li>
<li id="CR127">
<span class="label">127.</span><cite>Alkhouri N, Fraessdorf M, Neff G, et al. Survodutide reduces liver fat content, transaminases, and fibrosis markers with good safety profile in people with metabolic dysfunction-associated steatohepatitis (MASH): an interim analysis of a randomized, doulbe-blind, placebo-controlled phase 2 trial. Gastroenterology. 2024;166:1057a1. 10.1016/S0016-5085(24)05018-2.</cite> [<a href="https://scholar.google.com/scholar_lookup?Alkhouri%20N,%20Fraessdorf%20M,%20Neff%20G,%20et%20al.%20Survodutide%20reduces%20liver%20fat%20content,%20transaminases,%20and%20fibrosis%20markers%20with%20good%20safety%20profile%20in%20people%20with%20metabolic%20dysfunction-associated%20steatohepatitis%20(MASH):%20an%20interim%20analysis%20of%20a%20randomized,%20doulbe-blind,%20placebo-controlled%20phase%202%20trial.%20Gastroenterology.%202024;166:1057a1.%2010.1016/S0016-5085(24)05018-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR128">
<span class="label">128.</span><cite>De Sio V, Gragnano F, Capolongo A, et al. Eligibility for and practical implications of semaglutide in overweight and obese patients with acute coronary syndrome. Int J Cardiol. 2025;423:133028. 10.1016/j.ijcard.2025.133028.
</cite> [<a href="https://doi.org/10.1016/j.ijcard.2025.133028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39890028/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?De%20Sio%20V,%20Gragnano%20F,%20Capolongo%20A,%20et%20al.%20Eligibility%20for%20and%20practical%20implications%20of%20semaglutide%20in%20overweight%20and%20obese%20patients%20with%20acute%20coronary%20syndrome.%20Int%20J%20Cardiol.%202025;423:133028.%2010.1016/j.ijcard.2025.133028." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR129">
<span class="label">129.</span><cite>Hu S, Su X, Fan G. Efficacy and tolerability of the subcutaneous semaglutide for type 2 diabetes patients: an updated systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15:218. 10.1186/s13098-023-01195-7.
</cite> [<a href="https://doi.org/10.1186/s13098-023-01195-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10612199/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37891683/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hu%20S,%20Su%20X,%20Fan%20G.%20Efficacy%20and%20tolerability%20of%20the%20subcutaneous%20semaglutide%20for%20type%202%20diabetes%20patients:%20an%20updated%20systematic%20review%20and%20meta-analysis.%20Diabetol%20Metab%20Syndr.%202023;15:218.%2010.1186/s13098-023-01195-7." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR130">
<span class="label">130.</span><cite>Cleto AS, Schirlo JM, Beltrame M, et al. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Int J Obes. 2025;49:21–30. 10.1038/s41366-024-01646-9.</cite> [<a href="https://doi.org/10.1038/s41366-024-01646-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39396098/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cleto%20AS,%20Schirlo%20JM,%20Beltrame%20M,%20et%20al.%20Semaglutide%20effects%20on%20safety%20and%20cardiovascular%20outcomes%20in%20patients%20with%20overweight%20or%20obesity:%20a%20systematic%20review%20and%20meta-analysis.%20Int%20J%20Obes.%202025;49:21%E2%80%9330.%2010.1038/s41366-024-01646-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR131">
<span class="label">131.</span><cite>Aroda VR, Erhan U, Jelnes P, et al. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab. 2023;25:1385–97. 10.1111/dom.14990.
</cite> [<a href="https://doi.org/10.1111/dom.14990" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36700417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Aroda%20VR,%20Erhan%20U,%20Jelnes%20P,%20et%20al.%20Safety%20and%20tolerability%20of%20semaglutide%20across%20the%20SUSTAIN%20and%20PIONEER%20phase%20IIIa%20clinical%20trial%20programmes.%20Diabetes%20Obes%20Metab.%202023;25:1385%E2%80%9397.%2010.1111/dom.14990." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR132">
<span class="label">132.</span><cite>Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024. 10.1001/jamaophthalmol.2024.2296.</cite> [<a href="https://doi.org/10.1001/jamaophthalmol.2024.2296" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11223051/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38958939/" class="usa-link">PubMed</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM1_ESM.docx</a><sup> (18.9MB, docx) </sup><p>Additional file 1. Supplementary methods and results, list of excluded trials, search strategies, Tables S1-2, Figure S1-99. Figure S1—PRISMA checklist. Figure S2—Forest plot of all-cause mortality. Figure S3—TSA of all-cause mortality. Figure S4—Beta-binomial regression of all-cause mortality. Figure S5-S14—Subgroup analyses of all-cause mortality. Figure S15—Meta-regression of all-cause mortality. Figure S16—Forest plot of serious adverse events. Figure S17—Beta-binomial regression of serious adverse events. Figure S18—TSA of serious adverse events. Figure S19-32 – Subgroup analyses of serious adverse events. Figure S33 – Meta-regression of serious adverse events. Figure S34-35 – Forest plots of harmful individual SAEs. Figure S36-51 – Forest plots of beneficial SAEs. Figure S52-99 – Forest plot of individual SAEs showing no signs of a difference.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM2_ESM.docx</a><sup> (19MB, docx) </sup><p>Additional file 2. Figure S100-285 - Forest plot of individual SAEs showing no signs of a difference.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM3_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM3_ESM.docx</a><sup> (18.9MB, docx) </sup><p>Additional file 3. Figure S286-471. Figure S286-471 - Forest plot of individual SAEs showing no signs of a difference.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM4_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM4_ESM.docx</a><sup> (17.5MB, docx) </sup><p>Additional file 4. Figure S472-618. Figure S472-595 - Forest plot of individual SAEs showing no signs of a difference. Figure S596-597 – Forest plots of myocardial infarction. Figure S598 – TSA of myocardial infarction. Figure S599 – Beta-binomial regression of myocardial infarction. Figure S600-611 – Subgroup analyses of myocardial infarction. Figure S612-613 – Forest plots of stroke. Figure S614 – TSA of stroke. Figure S615 – Beta-binomial regression of stroke. Figure S616-617 – Forest plots of all-cause hospitalization. Figure S618 – TSA of all-cause hospitalization.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material5_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM5_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM5_ESM.docx</a><sup> (18.8MB, docx) </sup><p>Additional file 5. Figure S619-620 – Forest plots of non-serious adverse events. Figure S621 – TSA of non-serious adverse events. Figure S622-661 – Forest plots of harmful individual non-serious adverse events. Figure S662-671 – Forest plots of beneficial individual non-serious adverse events. Figure S672-719 – Forest plots of individual non-serious adverse events showing no signs of a difference. Figure S720-721 – Forest plots of pancreatitis. Figure S722 – TSA of pancreatitis. Figure S723 – Beta S720-721 – Forest plots of pancreatitis. Figure S722 – TSA of pancreatitis. Figure S723 – Betabinomial regression of pancreatitis. Figure S724-725 – Forest plots of cancer. Figure S726 – TSA of cancer. Figure S727 – Beta-binomial regression of cancer. Figure S728-729 – Forest plots of suicide and suicide attempt. Figure S730 – TSA of suicide and suicide attempt. Figure S731 – Beta binomial regression of suicide and suicide attempt. Figure S732-733 – Forest plots of the composite outcome. Figure S734 – TSA of composite outcome. Figure S735-736 – Forest plots of vision change. Figure S737 – TSA of vision change. Figure S738 – Beta-binomial regression of vision change.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material6_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12642075/bin/12916_2025_4486_MOESM6_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12916_2025_4486_MOESM6_ESM.docx</a><sup> (6MB, docx) </sup><p>Additional file 6. Figure S739-790. Figure S739-744 – Additional post-hoc subgroup analyses. Figure S745-746 – Post-hoc metaanalyses of ischemic anterior neuropathy. Figure S747-778 – Test for publication bias for all outcomes. Figure S779-790 – Post-hoc sensitivity analyses.</p>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The dataset supporting the conclusions of this article is included within the article (and its additional file).
</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from BMC Medicine are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12916-025-04486-0"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12916_2025_Article_4486.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.5 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12642075/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12642075/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12642075%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12642075/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12642075/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12642075/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/41286875/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12642075/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/41286875/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12642075/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12642075/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="eSa33dtjHaNl4ZtyLmDYnb4J932sywzmxROFSh0AzVfLLdJ5TmY0JjEBXwPZkjof">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-B7-tgZZA.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-BLbQGH8u.js"></script>
    
    

    </body>
</html>
